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A B S T R A C T
Background
Asthma exacerbations can be frequent and range in severity from mild to life-threatening. The use of magnesium sulfate (MgSO )
is one of numerous treatment options available during acute exacerbations. While the efficacy of intravenous MgSO has been
demonstrated, the role of inhaled MgSO is less clear.
Objectives
To determine the efficacy and safety of inhaled MgSO administered in acute asthma.
Specific aims: to quantify the effects of inhaled MgSO I) in addition to combination treatment with inhaled β -agonist and
ipratropium bromide; ii) in addition to inhaled β -agonist; and iii) in comparison to inhaled β -agonist.
Search methods
We identified randomised controlled trials (RCTs) from the Cochrane Airways Group register of trials and online trials registries in
September 2017. We supplemented these with searches of the reference lists of published studies and by contact with trialists.
Selection criteria
RCTs including adults or children with acute asthma were eligible for inclusion in the review. We included studies if patients were
treated with nebulised MgSO alone or in combination with β -agonist or ipratropium bromide or both, and were compared with
the same co-intervention alone or inactive control.
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Data collection and analysis
Two review authors independently assessed trial selection, data extraction and risk of bias. We made efforts to collect missing data from
authors. We present results, with their 95% confidence intervals (CIs), as mean differences (MDs) or standardised mean differences
(SMDs) for pulmonary function, clinical severity scores and vital signs; and risk ratios (RRs) for hospital admission. We used risk
differences (RDs) to analyse adverse events because events were rare.
Main results
Twenty-five trials (43 references) of varying methodological quality were eligible; they included 2907 randomised patients (2777
patients completed). Nine of the 25 included studies involved adults; four included adult and paediatric patients; eight studies enrolled
paediatric patients; and in the remaining four studies the age of participants was not stated. The design, definitions, intervention and
outcomes were different in all 25 studies; this heterogeneity made direct comparisons difficult. The quality of the evidence presented
ranged from high to very low, with most outcomes graded as low or very low. This was largely due to concerns about the methodological
quality of the included studies and imprecision in the pooled effect estimates.
Inhaled magnesium sulfate in addition to inhaled β -agonist and ipratropium
We included seven studies in this comparison. Although some individual studies reported improvement in lung function indices
favouring the intervention group, results were inconsistent overall and the largest study reporting this outcome found no between-
group difference at 60 minutes (MD −0.3 % predicted peak expiratory flow rate (PEFR), 95% CI −2.71% to 2.11%). Admissions
to hospital at initial presentation may be reduced by the addition of inhaled magnesium sulfate (RR 0.95, 95% CI 0.91 to 1.00;
participants = 1308; studies = 4; I² = 52%) but no difference was detected for re-admissions or escalation of care to ITU/HDU. Serious
adverse events during admission were rare. There was no difference between groups for all adverse events during admission (RD 0.01,
95% CI −0.03 to 0.05; participants = 1197; studies = 2).
Inhaled magnesium sulfate in addition to inhaled β -agonist
We included 13 studies in this comparison. Although some individual studies reported improvement in lung function indices favouring
the intervention group, none of the pooled results showed a conclusive benefit as measured by FEV1 or PEFR. Pooled results for
hospital admission showed a point estimate that favoured the combination of MgSO and β -agonist, but the confidence interval
includes the possibility of admissions increasing in the intervention group (RR 0.78, 95% CI 0.52 to 1.15; participants = 375; studies
= 6; I² = 0%). There were no serious adverse events reported by any of the included studies and no between-group difference for all
adverse events (RD −0.01, 95% CI −0.05 to 0.03; participants = 694; studies = 5).
Inhaled magnesium sulfate versus inhaled β -agonist
We included four studies in this comparison. The evidence for the efficacy of β -agonists in acute asthma is well-established and
therefore this could be considered a historical comparison. Two studies reported a benefit of β -agonist over MgSO alone for PEFR
and two studies reported no difference; we did not pool these results. Admissions to hospital were only reported by one small study
and events were rare, leading to an uncertain result. No serious adverse events were reported in any of the studies in this comparison;
one small study reported mild to moderate adverse events but the result is imprecise.
Authors’ conclusions
Treatment with nebulised MgSO may result in modest additional benefits for lung function and hospital admission when added to
inhaled β -agonists and ipratropium bromide, but our confidence in the evidence is low and there remains substantial uncertainty.
The recent large, well-designed trials have generally not demonstrated clinically important benefits. NebulisedMgSO does not appear
to be associated with an increase in serious adverse events. Individual studies suggest that those with more severe attacks and attacks of
shorter duration may experience a greater benefit but further research into subgroups is warranted.
Despite including 24 trials in this review update we were unable to pool data for all outcomes of interest and this has limited the strength
of the conclusions reached. A core outcomes set for studies in acute asthma is needed. This is particularly important in paediatric studies
where measuring lung function at the time of an exacerbation may not be possible. Placebo-controlled trials in patients not responding
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to standard maximal treatment, including inhaled β -agonists and ipratropium bromide and systemic steroids, may help establish if
nebulised MgSO has a role in acute asthma. However, the accumulating evidence suggests that a substantial benefit may be unlikely.
P L A I N L A N G U A G E S U M M A R Y
Is inhaled magnesium sulfate a safe and effective treatment for people with asthma attacks?
Background
Asthma attacks are common in adults and children. People having an attack may need to be treated in a hospital emergency department
(A&E). Even with the best treatment, some people need to be admitted to hospital or even into the intensive care unit. Some guidelines
suggest that giving magnesium sulfate, either by injection or inhaled straight into the lungs, may be beneficial. In this review we focused
on inhaled (or ’nebulised’) magnesium sulfate. We were particularly interested in finding out the effects of magnesium sulfate on lung
function (breathing tests), severity scores and hospital admissions. We also wanted to know if it was safe.
Study characteristics
We looked for studies in adults and children attending the emergency department with an asthma attack. We included studies which
compared giving inhaled magnesium sulfate, plus standard treatment, with standard treatment alone. We also included studies that
compared inhaled magnesium sulfate directly with standard treatment. We included studies carried out anywhere in the world, at any
time and written in any language.
Key results
We found 25 studies in total, which included nearly 3000 people with asthma attacks. This latest update of the review includes several
large trials that were carried out to a very high standard. We found that adding inhaled magnesium sulfate to standard treatments may
result in small benefits in terms of lung function, hospital admission and severity scores, but we are uncertain about these findings.
This is because many of the studies were carried out in different ways and measured different outcomes at different times so it was
quite hard to combine the results from individual studies. Inhaled magnesium sulfate did not seem to cause any serious side effects in
the studies we found. We did not find evidence that using inhaled magnesium sulfate instead of standard treatment is beneficial.
Quality of the evidence
We used a scoring system to rate how confident we are in the findings presented. Our scores ranged from high confidence to very low
confidence, but most outcomes we rated as low or very low. This is because we had concerns about the way in which some of the studies
were carried out: for example, it was perhaps not clear how people were chosen for the two different treatment groups in the study; or
it was unclear whether the patients or people running the trial knew who was getting which treatment. Another factor that reduced
our confidence was uncertainty about the combined results: for example in some cases we could not tell whether magnesium sulfate
was better, worse or the same.
Key message
There is some limited evidence that inhaled magnesium sulfate may have a small benefit for people having asthma attacks when added
to standard treatment. However, the most recent, high-quality trials did not generally show important benefits. Also, we cannot be sure
if some groups may benefit more than other, for example those having more severe attacks.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
MgSO + SABA + ipratropium compared to SABA + ipratropium in the treatment of acute asthma
Patient or population: adults and children with acute exacerbat ion of asthma
Setting: emergency department/ inpat ient
Intervention: MgSO + SABA + ipratropium
Comparison: SABA + ipratropium
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with SABA + ipra-
tropium
Risk with MgSO4 +
SABA + ipratropium
Pulmonary funct ion (%
predicted FEV1)
(90 to 120 minutes)
The mean pulmonary
funct ion (% predicted
FEV1) was 65%
% predicted FEV1 was
3.28% higher
(1.06 higher to 5.49
higher)
- 120
(2 RCTs)
⊕©©©
VERY LOW 123
Outcome measured at
90 mins in 1 study and
120 mins in the other
1 study (Gaur 2008)
has reported much
smaller standard devi-
at ions and contributes
almost 90% of analysis
weight
Pulmonary funct ion %
predicted PEF
(60 minutes)
The mean pulmonary
funct ion % predicted
PEF was 50.45%
% predicted PEF was 0.
05 higher
(2.33 lower to 2.42
higher)
- 636
(2 RCTs)
⊕⊕⊕©
MODERATE 245
Both studies in adults
Mean control group %
predicted PEF was 36%
in 1 study and 64.9% in
the other
Clinical severity scores
(60 minutes)
The mean dyspnoea
VASwas 31.8; the mean
Yung ASS was 4.95
SMD 0.01 higher
(0.11 lower to 0.12
higher)
- 1130
(2 RCTs)
⊕⊕©©
LOW 26
1 study reported Yung
ASS and the other
change in dyspnoea
VAS
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Admission at f irst pre-
sentat ion
819 per 1000 778 per 1000
(745 to 819)
RR 0.95
(0.91 to 1.00)
1308
(4 RCTs)
⊕⊕⊕©
MODERATE 789
Adults vs children test
for subgroup dif fer-
ence: P = 0.72, I² = 0%
Readmission
(7 to 30 days)
26 per 1000 46 per 1000
(22 to 100)
RR 1.80
(0.84 to 3.87)
750
(2 RCTs)
⊕⊕©©
LOW 10
Outcome measured at
7 days in 1 study and
30 days in the other
Serious adverse events
(during admission)
43 per 1000 Not est imable. See
comment.
- 557
(2 RCTs)
⊕⊕⊕©
MODERATE 11
Risk dif ference: −0.03
(95% CI −0.06 to 0.00)
Adults vs children test
for subgroup dif fer-
ence: P = 0.39, I² = 0%
Goodacre 2013 also
reported part icipants
with 1 or more SAE
within 30 days: 35/ 332
in the MgSO group and
28/ 358 in the placebo
group (RD: 0.03; 95%CI
−0.02 to 0.07)
Any adverse event (dur-
ing admission)
144 per 1000 Not est imable. See
comment.
- 1197
(2 RCTs)
⊕⊕⊕⊕
HIGH
Risk Dif ference: 0.01
(95% CI −0.03 to 0.05)
Adults vs children test
for subgroup dif fer-
ence: P = 0.34, I² = 0%
Goodacre 2013 also
reported part icipants
with 1 or more adverse
event within 30 days:
52/ 332 in the MgSO
group and 36/ 358 in the
placebo group (OR 1.
66, 95%CI 1.05 to 2.62)
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ASS: asthma severity score; CI: Conf idence interval; RD: risk dif f erence; RR: Risk rat io; OR: Odds rat io; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 One study contribut ing most of weight at unclear risk of bias in mult iple domains (−1 study lim itat ions)
2 I² > 50% (−1 inconsistency)
3 Studies equal size but one study contributes almost 90% of weight to analysis due to much smaller standard deviat ions.
Result no longer signif icant if random-ef fects model applied (−1 imprecision)
4 Although one study at unclear risk of bias in several domains, the larger study, which contributes vast majority of weight to
analysis, if of high methodological quality (no downgrade)
5 Although conf idence interval includes no dif ference, they are suf f icient ly t ight to ef fect ively rule out an important between-
group dif ference (no downgrade)
6 Conf idence intervals include both harm and benef it of intervent ion (−1 imprecision)
7 Although two of the studies at unclear risk of bias in several domains the two large studies contribut ing nearly 95%of weight
in analysis are both of high methodological quality (no downgrade)
8 Although the I² = 52%, the two large studies contribut ing to this analysis show consistent results (no downgrade)
9 Conf idence intervals include no dif ference (−1 imprecision)
10 Conf idence intervals include no dif ference and appreciable harm or benef it of the intervent ion (−2 imprecision)
11 Events rare and conf idence intervals include no dif ference (−1 imprecision)
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B A C K G R O U N D
Description of the condition
Asthma is a chronic respiratory disease characterised by reversible
airflow obstruction, with periods of relative control and episodes
of deterioration referred to as exacerbations. Exacerbations range
in severity from mild to life-threatening and can result in visits to
healthcare providers and emergency departments, at times neces-
sitating hospital admission. While rare, admissions to the inten-
sive care setting, mechanical ventilation and deaths from severe
acute asthma exacerbations do still occur (NRAD 2014): thus the
prevention and treatment of exacerbations are important consid-
erations for everyone with asthma. Due to its chronicity, variabil-
ity, risk of mortality, and cost to the healthcare system, asthma
remains the cause of significant personal and social burden.
Description of the intervention
Asthma exacerbations are characterised by acute episodes of bron-
choconstriction and airway inflammation. These episodes gener-
ally result in increased requirements for inhaled beta -agonist
(β -agonist) therapy (Cates 2004). Unfortunately, in acute asth-
matic episodes, β -agonists may not be enough to relieve bron-
chospasm and reduce dyspnoea. The evidence-based guideline for
the management of asthma developed by the British Thoracic So-
ciety (BTS) and the Scottish Intercollegiate Guideline Network
(SIGN) offers comprehensive guidance on the acute and chronic
management of asthma in children and adults (BTS/SIGN 2016).
Although the management of children and adults is broadly sim-
ilar, differences remain between the management of acute exacer-
bations of asthma in children (less than 16 years old) and adults
(16 years and older) (BTS/SIGN 2016).
For children and adults seen in an emergency department (ED
or A&E) with an asthma exacerbation, the BTS/SIGN guideline
recommends inhaled or nebulised β -agonists, systemic corticos-
teroids, and oxygen if needed. International guidelines also rec-
ommend the use of inhaled ipratropium for all adults, and chil-
dren over the age of 5 with severe exacerbations (GINA 2017). For
poorly responsive children the next step is nebulised ipratropium
(if not already given), and consideration of nebulised magnesium
sulfate (MgSO ) if life-threatening features are identified. Intra-
venous (IV)MgSO (Shan2013), salbutamol and aminophylline
are considered if response remains poor. For poorly responsive
adults, or those with a life-threatening exacerbation, the addition
of nebulised ipratropium (if not already given) is recommended,
with consideration of IV MgSO (Kew 2014). Nebulised mag-
nesium sulfate is not recommended for the treatment of adults
with acute asthma (BTS/SIGN 2016).
How the intervention might work
Magnesium sulfate has been proposed as a possible additive treat-
ment in acute asthma, and has been shown to be effective in se-
vere acute asthma when delivered intravenously (Shan 2013; Kew
2014). It may be effective in acute asthma through one or more of
a variety of mechanisms. There is evidence that magnesium sulfate
may augment the beta receptor response to salbutamol (Turner
2017). Magnesium sulfate has been shown to relax smooth mus-
cle by inhibiting calcium ion influx (Gourgoulianis 2001); it in-
hibits acetylcholine and histamine release from cholinergic motor
nerve terminals andmast cells respectively (DelCastillo 1954; Bois
1962), and promotes synthesis of nitric oxide (Ashutosh 2000)
and prostacyclin (Nadler 1987), which stimulate broncho- and
vasodilation. Finally,magnesium ions may have an anti-inflamma-
tory role, attenuating neutrophil activation in adults with asthma
(Cairns 1996).
Why it is important to do this review
The potential clinical benefits of nebulised MgSO have been
studied and research publications have produced conflicting re-
sults. Subgroup analysis from one large multi-centre RCT sug-
gests a possible role for MgSO in the treatment of children with
acute severe asthma (Powell 2013), and has led to current guid-
ance to consider nebulisedMgSO for children presenting with a
life-threatening acute asthma attack (BTS/SIGN 2016). However,
nebulised MgSO has not yet been used widely in the acute care
setting.
In the previous version of this Cochrane Review (Powell 2012),
sixteen trials involving 896 patients were included. Seven studies
compared nebulised MgSO with β -agonist to β -agonist
alone, three studies compared nebulised MgSO to β -agonist
alone, and two studies compared nebulised MgSO with β -
agonist and ipratropium to β -agonist and ipratropium alone.
The review concluded that therewas no good evidence that inhaled
MgSO could be used as a substitute for inhaled β -agonists;
and when used in addition to standard inhaled treatments there
was no clear evidence of improved pulmonary function or reduced
hospital admissions. However, individual study results from three
trials suggest possible improved pulmonary function in those with
severe asthma exacerbations. The review called for further studies
focusing on inhaled MgSO in addition to the current guideline
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treatment for acute asthma and including those with more severe
exacerbations.
A 2013 systematic review including nine trials of nebulised mag-
nesium sulfate (some of which were excluded from the 2012
Cochrane Review) identified benefits in pulmonary function for
adults treated with nebulised magnesium sulfate compared to
placebo (Shan 2013).
Thus, MgSO administration in combination with β -agonists
may be of benefit with respect to pulmonary function in patients
presenting to the emergency department with severe acute exac-
erbations of asthma, and there may be evidence that MgSO ad-
ministered in combination with β -agonists reduces hospitali-
sations. Due to significant heterogeneity among studies, both in
terms of treatments and outcome measures, there remains a need
for further trials before recommendations can be made regarding
the use of nebulised magnesium sulfate for acute asthma exacerba-
tions. The rationale for completing this updated systematic review
was to examine the influence any further studies would make on
these conclusions.
O B J E C T I V E S
To determine the efficacy and safety of inhaled MgSO admin-
istered in acute asthma.
Specific aims: to quantify the effects of inhaled MgSO I) in
addition to combination treatment with inhaled β -agonist and
ipratropium bromide, ii) in addition to inhaled β -agonist and
iii) in comparison to inhaled β -agonist.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised (or quasi-randomised) controlled trials.
We included only parallel study designs; cross-over trials were ex-
cluded.
Types of participants
We included studies restricting enrolment to patients with acute
asthma; patients with chronic or ’stable’ asthma were excluded
from the review. We included studies involving all ages; however,
we sub-grouped data into adults and children where possible. We
accepted any reasonable diagnosis of asthma, namely clinical and
guideline-based criteria.
Types of interventions
We included studies where participants were randomised to receive
inhaledMgSO comparedwith a control inhaled treatment. That
is, studies comparing the efficacy of:
• inhaled MgSO and β -agonist and ipratropium versus
β -agonist and ipratropium and placebo;
• inhaled MgSO and β -agonist versus β -agonist and
placebo;
• inhaled MgSO versus β -agonist.
We allowed co-interventions, and recorded information we re-
ceived about them.
Types of outcome measures
Primary outcomes
Change in pulmonary function from baseline using the following
indices.
1. Forced expiratory volume in one second (FEV1) and
percentage predicted FEV1;
2. Peak expiratory flow (PEF) and percentage predicted PEF.
Secondary outcomes
1. Clinical severity scores.
2. Proportion of patients requiring admission to hospital.
3. Duration of symptoms.
4. Vital signs (pulse and respiratory rates; systolic and diastolic
blood pressure).
5. Adverse events (tremor, nausea, etc).
For the 2017 update, we chose to extract and present outcomes
including lung function, vital signs and severity scores at - or as
close as possible to - 60 minutes post-baseline. The rationale for
this decision is given in the Potential biases in the review process
section.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
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The Cochrane Airways Trials Register contains studies identified
from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP 1946 to date.
3. Weekly searches of Embase Ovid SP 1974 to date.
4. Monthly searches of PsycINFO Ovid SP 1967 to date.
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature) 1937 to date.
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine).
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings are in Appendix 1. See Appendix 2 for the search terms
we used to identify studies for this review.
We also conducted a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and theWorld Health
Organization (WHO) trials portal (apps.who.int/trialsearch) (Ap-
pendix 2). We searched all sources from their inception to the
present and we placed no restriction on the language of publica-
tion. Search methods used in the previous version of this review
are detailed in Appendix 3. The previously published version in-
cluded searches up to September 2012. The search period for this
update is September 2012 to 6 September 2017.
Searching other resources
We examined the reference lists of all selected articles, primary
studies and review articles for relevant studies. We contacted pri-
mary authors of studies to request information on additional trials
(published and unpublished). We contacted clinicians, colleagues,
collaborators and trialists to identify potentially relevant studies.
Since MgSO is not currently commercially delivered, we did
not contact any industry sponsor.
Data collection and analysis
Selection of studies
The selection of studies involved two steps. First, to retrieve studies
two independent investigators screened by title, abstract, MeSH
headings and keywords the initial search of all databases and ref-
erence lists to identify all citations of randomised controlled trials
(RCTs) or possible RCTs with potential relevance. We obtained
the full texts of those selected articles for ’formal inclusion’ review.
Second, another review author independently decided on trial in-
clusion using pre-determined eligibility criteria.
Data extraction and management
We extracted data independently using a standardised data collec-
tion form. We extracted the following information, if available:
characteristics of the study (design, methods of randomisation,
withdrawals/dropouts); participants (age, gender); intervention
(type, dose, route of administration, timing and duration of ther-
apy, co-interventions); control (agent and dose); outcomes (types
of outcome measures measured and reported, timing of outcomes,
adverse events); and results. We requested unpublished data from
the primary authors when necessary. For this update, two review
authors (RK and RN) entered data into Review Manager 2014.
Assessment of risk of bias in included studies
We applied the Cochrane ’Risk of bias’ tool in this 2017 update
(Higgins 2011). Two review authors (RK and RN) independently
assessed the risk of bias for all new included studies for the fol-
lowing six items: random sequence generation; allocation conceal-
ment; blinding; incomplete outcome data; selective outcome re-
porting; and other types of bias. We recorded the judgement as
high, low or unclear risk of bias and added a description from the
trial reports. We discussed any disagreements and resolved them
by consensus.
Measures of treatment effect
For dichotomous variables, we expressed data as risk ratio (RR)
with 95% confidence intervals (CIs) and reported adverse events
as risk difference (RD) together with 95% CIs. For the contin-
uous variables ’pulmonary function’ and ’clinical severity score’,
we reported data as mean differences (MD) or standardised mean
differences (SMD) with 95% CIs.
Unit of analysis issues
The unit of analysis was the patient.
Dealing with missing data
If baseline or outcome data or information on trial design were
missing, we attempted to contact trial authors.
Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the forest plots.
We also used the Chi² test (where a P value < 0.10 indicates sub-
stantial heterogeneity); however, we exercised caution in interpre-
tation due to the low power associated with this test. I² was calcu-
lated and a guide to interpretation is:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity (Higgins 2011).
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Assessment of reporting biases
We planned to test for publication bias using a funnel plot if there
was a sufficient number of trials included in a single forest plot
(more than 10). It should be noted that an asymmetrical funnel
plot can be caused by heterogeneity, outcome reporting bias and
small-study effects as well as publication bias.
Data synthesis
We combined data using a fixed-effect model except in cases where
we identified substantial heterogeneity, as defined above, where we
employed a random-effects model as a sensitivity analysis.
Subgroup analysis and investigation of heterogeneity
A priori subgroup analyses were planned to examine the effect of:
1. age (two to 16 years old (paediatric) and > 16 years old
(adult));*
2. severity of asthma as measured by pre-administration
spirometric deviation from predicted (baseline FEV1 or PEF <
50% predicted).
*For the 2017 update, if the age range of participants was unclear,
we classified the study according to average age of participants.
Sensitivity analysis
We planned to conduct sensitivity analyses to assess the effect of
the overall risk of bias of included trials, but there were insuffi-
cient trials of varied methodological quality in the meta-analysis
for a sensitivity analysis (e.g. either all the studies were of similar
methodological quality, or removing a trial in which we had con-
cerns about risk of bias made no difference to the pooled result).
For the 2017 update we performed a post-hoc sensitivity analysis
using a random-effects model when we encountered a study with
unusually small standard deviations, which was therefore domi-
nating the meta-analysis. Results of such random-effects model
meta-analyses should be interpreted with caution as the model is
based on the assumption of a normal distribution of the true effect
from each study; this is problematic in analyses with few studies.
We also employed a random-effects model as a sensitivity analysis
if substantial heterogeneity was detected, as previously described.
’Summary of findings’ table
For this update we included a ’Summary of findings’ table for
each main comparison and assessed the quality of the evidence
using the five GRADE domains (study limitations, imprecision,
inconsistency, indirectness and publication bias). We decided a
priori to include lung function, clinical severity scores, hospital
admissions and adverse events. We used GRADEPro software (
GRADEpro GDT) to create the ’Summary of findings’ tables.
R E S U L T S
Description of studies
Results of the search
The previous version of the review included 16 trials. For this up-
date, the database search yielded 45 records and we identified six
records from additional sources. Fourteen records were excluded
on the basis of the title or abstract and we assessed 37 full texts
for eligibility. We excluded a further 10 full texts, with reasons,
and identified three ongoing studies. We included nine new stud-
ies (22 records) in the review, bringing the total number of in-
cluded studies to 25 (43 records). See Figure 1, Characteristics of
excluded studies and Characteristics of ongoing studies for fur-
ther details. In addition, we moved two studies which had previ-
ously been excluded to Studies awaiting classification (Abd 1997;
Bustamante 2000); and added one additional study to Studies
awaiting classification (ISRCTN61336225)
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Figure 1. Study flow diagram: review update
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Included studies
We incorporated 25 trials (43 references) including 2907 ran-
domised participants (2777 of whom completed) into the review
(see Characteristics of included studies). All of the studies included
in this manuscript were published since 1995. There is no par-
ticular geographic preference, with Argentina, Egypt, India, Iran,
Mexico, New Zealand, Tenerife, Turkey, the UK and the USA
represented.
We requested lung function data from the primary authors for two
included studies (Meral 1996; Drobina 2006); and further infor-
mation on trials design and baseline data from four authors (Neki
2006; Badawy 2014; Hossein 2016; Sarhan 2016). We also re-
quested clarificationon adverse event data fromone author (Powell
2013). With the exception of clarification from the authors of
Badawy 2014 and Powell 2013 we did not receive a reply before
this review was published. Should information subsequently be-
come available, we will include it in a future update.
Populations
Nine of the 25 included studies involved adults exclusively
(Nannini 2000; Abreu-Gonzalez 2002; Bessmertny 2002;Hughes
2003; Kokturk 2005; Gaur 2008; Gallegos-Solórzano 2010;
Goodacre 2013;Hossein 2016); and four included adults and chil-
dren (Mangat 1998; Aggarwal 2006; Neki 2006; Sarhan 2016).
Eight studies enrolled children (Meral 1996; Mahajan 2004;
Ashtekar 2008; Khashabi 2008; Powell 2013; Mohammedzadeh
2014; Alansari 2015; Turker 2017); and in the remaining four
studies the age of participants was not stated (Dadhich 2005;
Drobina 2006; Ahmed 2013; Badawy 2014).
The severity of disease varied between studies (Table 1). Fourteen
studies enrolled patients based on specific lung function criteria
(Meral 1996; Mangat 1998; Nannini 2000; Bessmertny 2002;
Hughes 2003; Mahajan 2004; Dadhich 2005; Neki 2006; Gaur
2008; Gallegos-Solórzano 2010; Goodacre 2013; Powell 2013;
Alansari 2015; Hossein 2016), while the remaining studies en-
rolled patients previously diagnosed with asthma using accepted
clinical standards, or did not specify how asthma was diagnosed.
Based on the baseline demographic data, 15 studies were con-
sidered to enrol severe acute exacerbations of asthma (FEV1 or
PEF < 50% predicted at baseline or symptom criteria defined by
BTS/SIGNguideline) (Meral 1996;Mangat 1998;Nannini 2000;
Bessmertny 2002; Hughes 2003; Mahajan 2004; Dadhich 2005;
Kokturk 2005; Aggarwal 2006; Neki 2006; Ashtekar 2008; Gaur
2008; Gallegos-Solórzano 2010; Goodacre 2013; Powell 2013).
Sixteen studies recruited participants from emergency depart-
ments; two from outpatient or emergency departments (Badawy
2014; Sarhan 2016); and one in a children’s assessment unit after
general practitioner referral (Ashtekar 2008). Department of pre-
sentation was unclear in the remaining six studies (see Table 2).
Badawy 2014 recruited exclusively pregnant women. Due to con-
cerns about baseline imbalance in this study, and the narrow pop-
ulation recruited, we did not include this study in our meta-anal-
yses and instead present the results narratively. The study has been
included in another Cochrane Review that addresses asthma treat-
ment options in pregnant women (Bain 2014).
Participants were excluded for a number of reasons including pre-
existing lung conditions and features of infection on examination.
There was great variation in pharmaceutical exclusion due to drugs
taken before recruitment (see Table 2).
Interventions
All studies used nebulised MgSO in the intervention group
but the comparison and placebo nebulised solutions varied (Table
3). Three studies compared MgSO with β -agonist directly
with no placebo (Meral 1996; Mangat 1998; Neki 2006). Twelve
studies compared β -agonist with MgSO to β -agonist with
placebo (normal saline) (Nannini 2000; Abreu-Gonzalez 2002;
Bessmertny 2002; Hughes 2003; Mahajan 2004; Kokturk 2005;
Aggarwal 2006; Khashabi 2008; Ahmed 2013; Badawy 2014;
Mohammedzadeh 2014; Turker 2017) . Five studies compared
β -agonist and ipratropium with MgSO to β -agonist and
ipratropium with placebo (Ashtekar 2008; Gaur 2008; Gallegos-
Solórzano 2010; Powell 2013; Hossein 2016), and Drobina 2006
compared β -agonist and ipratropium with MgSO to β -
agonist and ipratropium only (i.e. no placebo). Alansari 2015
compared β -agonist withMgSO to β -agonist with placebo
(normal saline) after both groups had received one hour of therapy
with combined β -agonist and ipratropium, and thus is included
in comparison one. Two studies had three groups and investi-
gated MgSO versus β -agonist versus MgSO plus β -ago-
nist (Dadhich 2005 and Sarhan 2016) and thus appear in compar-
isons 2 and 3. Goodacre 2013 studied one group with nebulised
MgSO , β -agonist, ipratropium and IV placebo, one with IV
MgSO , β -agonist, ipratropium and nebulised placebo, and
a third group with β -agonist, ipratropium and both nebulised
and IV placebo. The comparison involving IV MgSO has been
covered in other reviews (Kew 2014; Griffiths 2016).
Most studies used 0.9% normal saline as placebo; Aggarwal 2006
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used distilled water (as well as normal saline) for placebo and
Abreu-Gonzalez 2002 used ‘physiological serum’ as placebo.
We identified the following comparisons which have been used
throughout the review to lend structure.
• MgSO and β -agonist and ipratropium versus placebo
(saline) and β -agonist and ipratropium (seven studies:
Drobina 2006; Ashtekar 2008; Gaur 2008; Gallegos-Solórzano
2010; Goodacre 2013; Powell 2013; Hossein 2016).
• MgSO with β -agonist versus placebo (saline) and β -
agonist (15 studies: Nannini 2000; Abreu-Gonzalez 2002;
Bessmertny 2002; Hughes 2003; Mahajan 2004; Dadhich 2005;
Kokturk 2005; Aggarwal 2006; Khashabi 2008; Ahmed 2013;
Badawy 2014; Mohammedzadeh 2014; Alansari 2015; Sarhan
2016; Turker 2017).
• MgSO versus β -agonist alone (five studies: Meral
1996; Mangat 1998; Dadhich 2005; Neki 2006; Sarhan 2016).
Dose, formulation and dose frequency ofMgSO differed,mean-
ing that the overall dose ofMgSO given differed between studies
(Table 3). Not all studies reported the concentration of MgSO
nebulised, but when the information was available most included
studies used MgSO of similar concentration and osmolality.
However, dose per nebulisation and the number of nebulisations
performed varied.
Ten studies nebulised three doses of MgSO at 20 minutes inter-
vals (Bessmertny 2002; Hughes 2003; Aggarwal 2006; Ashtekar
2008; Gallegos-Solórzano 2010; Goodacre 2013; Powell 2013;
Mohammedzadeh 2014; Alansari 2015;Turker 2017). Three stud-
ies nebulised four doses at 20minute intervals (Mangat 1998;Neki
2006; Sarhan 2016). Kokturk 2005 nebulised hourly up to four
hours after the initial treatment of three doses in one hour. Five
studies nebulised only one treatment (Meral 1996; Nannini 2000;
Abreu-Gonzalez 2002; Mahajan 2004; Ahmed 2013). Khashabi
2008 gave two doses of treatment but the timing was unclear.
Three studies were unclear how frequently the doses were given
but probably only one dose was given (Dadhich 2005; Drobina
2006; Gaur 2008). One study gave up to three doses at 20 minute
intervals (Badawy 2014). Hossein 2016 gave treatments every 20
to 60 minutes but the total number of doses given was unclear.
All control or placebo interventions were similar in appearance
to the treatment drug. The most frequent placebo was saline.
One study collected data on participants’ ability to distinguish be-
tween the treatment and control, and noted no ability to discern (
Hughes 2003). Even when not expressly stated, it can reasonably
be assumed that the control (placebo) would be similar in appear-
ance to the treatment drug (especially if given in a β -agonist
vehicle).
Co-interventions
Co-interventions used added complexity and heterogeneity to
the review (Table 2). In 11 studies, systemic corticosteroids
were administered to all participants, although the timing (be-
fore/after nebulised treatment) varied (Mangat 1998; Hughes
2003; Mahajan 2004; Kokturk 2005; Neki 2006; Ashtekar 2008;
Gaur 2008; Badawy 2014; Alansari 2015; Sarhan 2016; Turker
2017). In one study, systemic corticosteroids were administered
if there was no improvement after the three doses of study treat-
ment (Bessmertny 2002). Overall, 15 studies routinely admin-
istered corticosteroids, but in different doses, routes and fre-
quency. In three studies, corticosteroids were administered ac-
cording to local standard/conventional treatment, or at the clini-
cians’ discretion (Aggarwal 2006; Goodacre 2013; Powell 2013).
Meral 1996 gave no further medication as a co-intervention. Six
studies made no comments on co-interventions (Nannini 2000;
Abreu-Gonzalez 2002; Dadhich 2005; Khashabi 2008; Ahmed
2013; Mohammedzadeh 2014).
Outcomes
A summary of the outcomes relevant to this review reported in the
included studies is given in Table 4.
Ongoing trials and unpublished data
We have identified three ongoing studies relevant to this review
(Motamed 2015; Saucedo 2015; Schuh 2016a).
Excluded studies
During the history of this review, 65 studies have been excluded
for the following reasons: 19 not acute asthma, 12 reviews articles,
11 not randomised controlled trials, eight investigated intravenous
magnesium sulfate, seven investigated oral supplements, two in-
vestigated intravenous versus inhaled magnesium sulfate, two let-
ters, one study unobtainable, one editorial, one study comparing
nebulised magnesium sulfate to ipratropium/fenoterol, and one
study in bronchiolitis (see Characteristics of excluded studies).
Risk of bias in included studies
See Figure 2 for summary of the risk of bias judgements.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Fourteen studies were described as ’randomised’ but themethod of
sequence generationwas not described; these studieswere therefore
at an unclear risk of bias (Abreu-Gonzalez 2002; Ahmed 2013;
Dadhich 2005; Drobina 2006; Gallegos-Solórzano 2010; Gaur
2008; Khashabi 2008; Kokturk 2005; Mangat 1998; Meral 1996;
Mohammedzadeh 2014; Nannini 2000; Sarhan 2016; Turker
2017). One further study was at an unclear risk of bias as it is not
clear if the study was randomised; we contacted the author for
clarification but received no response (Neki 2006). One study was
described as ‘randomised’ but no indication was given of random
sequence generation andwewere unable to confirm that the groups
were balanced with regard to baseline clinical asthma criteria; this
study was at high risk of bias (Badawy 2014).
Nine studies were at low risk of bias (Figure 2): the randomisa-
tion lists were computer-generated for four studies (Bessmertny
2002; Powell 2013; Alansari 2015; Hossein 2016); produced by
the pharmacy for two studies (Hughes 2003; Ashtekar 2008); pro-
duced by random number tables for two studies (Mahajan 2004;
Aggarwal 2006); and produced by a web-based randomisation sys-
tem for one study (Goodacre 2013).
No details, or minimal details, were provided on allocation con-
cealment in 17 studies; they were therefore assessed as at un-
clear risk of bias (Meral 1996; Mangat 1998; Nannini 2000;
Abreu-Gonzalez 2002; Hughes 2003; Dadhich 2005; Kokturk
2005; Drobina 2006; Neki 2006; Gaur 2008; Khashabi 2008;
Ahmed 2013; Badawy 2014; Mohammedzadeh 2014; Hossein
2016; Sarhan 2016; Turker 2017). A description of allocation con-
cealment was provided in eight studies and they were assessed as
at low risk of bias (Bessmertny 2002; Mahajan 2004; Aggarwal
2006; Ashtekar 2008; Gallegos-Solórzano 2010; Goodacre 2013;
Powell 2013; Alansari 2015).
Blinding
Fifteen studies gave details as to their double blinding and were
therefore at low risk of bias (Mangat 1998; Nannini 2000; Abreu-
Gonzalez 2002; Bessmertny 2002; Hughes 2003; Mahajan 2004;
Aggarwal 2006; Drobina 2006; Ashtekar 2008; Khashabi 2008;
Gallegos-Solórzano 2010; Goodacre 2013; Powell 2013; Alansari
2015; Hossein 2016). Two studies were single blind and therefore
at unclear risk of performance and assessment bias (Kokturk 2005;
Gaur 2008). One study was described as an open trial and was at
high risk of bias (Ahmed 2013).One study gave nobaseline clinical
asthmadata andnodetails about blinding andwas therefore at high
risk of detection bias (Badawy 2014). No details were provided
of blinding procedure or who was blinded for eight studies so we
deemed them to have an unclear risk of bias (Meral 1996;Dadhich
2005; Kokturk 2005; Neki 2006; Gaur 2008; Mohammedzadeh
2014; Sarhan 2016; Turker 2017).
Incomplete outcome data
Fourteen studies were at unclear risk of attrition bias for the follow-
ing reasons. Six studies were reported as conference abstracts only,
with no details provided regarding dropouts (Abreu-Gonzalez
2002; Dadhich 2005; Drobina 2006; Gaur 2008; Khashabi 2008;
Ahmed 2013); and no dropout data were given in six studies
(Meral 1996; Mangat 1998; Mahajan 2004; Neki 2006; Hossein
2016; Sarhan 2016). In Kokturk 2005 it appears as though there
were no dropouts but the published report states that a participant
was later excluded because the final diagnosis was COPD and the
treatment group is not stated.On further correspondence, Badawy
2014 gave appropriate reasons for exclusions, but details regarding
the groups from which participants were excluded were not given.
There was a high risk of bias in one study as three participants
were enrolled more than once; only the initial visit was used in the
analysis but the treatment group was not stated (Nannini 2000).
There was a low risk of bias in ten studies, with all randomised
participants completing in four studies (Aggarwal 2006; Ashtekar
2008; Mohammedzadeh 2014; Turker 2017); and reasons fully
described for dropouts in six studies (Bessmertny 2002; Hughes
2003; Gallegos-Solórzano 2010; Goodacre 2013; Powell 2013;
Alansari 2015).
Selective reporting
Ten studies were at unclear risk of reporting bias. Six studies were
only reported in conference abstracts and therefore the risk of se-
lective reporting bias is unclear (Abreu-Gonzalez 2002; Dadhich
2005; Drobina 2006; Neki 2006; Ashtekar 2008; Ahmed 2013).
Hossein 2016 was also at unclear risk of bias as not all primary out-
come data were reported, adverse events were recorded only as “no
treatment-related complications” and there were clear mistakes in
the reporting of vital signs. Sarhan 2016 did not distinguish be-
tween primary or secondary outcomes, while Mangat 1998 men-
tioned but did not report two outcomes.
Seven studies were judged to be at high risk of bias. One study was
considered at high risk of bias as outcomes were partially reported
and not statistically significant (Gaur 2008). Badawy 2014 was at
high risk of bias as no primary outcome was stated. On further
correspondence, adverse event data but no clinical asthma baseline
characteristics were given. Bessmertny 2002 did not present data
for outcomes which were described as not statistically significant,
and only means were presented for FEV1. We did not identify a
prospective trial registration for Turker 2017, adverse events were
reported as “no side effect caused by magnesium was observed
in any of the patients in the study” and the modified pulmonary
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index score was reported numerically at 120 minutes only. Hughes
2003, Meral 1996 and Nannini 2000 were also at high risk of bias
as the trial report stated there was no difference in blood pressure
and heart rate between the groups and no data were reported.
Eight studies were judged to be at low risk of bias. Four studies
were at low risk of bias as all outcomes stated in the methods were
reported, although no protocols were available (Mahajan 2004;
Kokturk 2005; Aggarwal 2006; Gallegos-Solórzano 2010). Pre-
registered protocols were available for four studies, in which all
planned outcomes were reported (Goodacre 2013; Powell 2013;
Mohammedzadeh 2014; Alansari 2015).
Other potential sources of bias
No other risks of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison MgSO4
+ SABA + ipratropium compared to SABA + ipratropium in
the treatment of acute asthma; Summary of findings 2 MgSO4
+ SABA compared to SABA in the treatment of acute asthma;
Summary of findings 3 MgSO4 compared to SABA in the
treatment of acute asthma
As detailed in the Methods section, we have presented effects of
interventions within the following comparisons.
• MgSO and β -agonist and ipratropium versus placebo
(saline) and β -agonist and ipratropium (comparison 1).
• MgSO with β -agonist versus placebo (saline) and β -
agonist (comparison 2).
• MgSO versus β -agonist alone (comparison 3).
MgSO and β -agonist and ipratropium versus
placebo (saline) and β -agonist and ipratropium
(comparison 1)
Pulmonary function
Four studies including1279participants reported onFEV1or PEF
(Gaur 2008; Gallegos-Solórzano 2010; Goodacre 2013; Hossein
2016).
Gallegos-Solórzano 2010 and Gaur 2008, both adult studies, re-
ported a greater %FEV1 in the MgSO and β -agonist and
ipratropium group at 90 minutes (MD: 8.57, 95% CI 1.99 to
15.15; participants = 60) and 120 minutes (MD: 2.60, 95% CI
0.25 to 4.95; participants = 60) respectively with the pooled fixed-
effect result favouring the MgSO intervention (MD 3.28, 95%
CI 1.06 to 5.49; participants = 120; studies = 2; I² = 64%; Analysis
1.1).
Despite being similar-sized studies, Gaur 2008 contributed nearly
90% of the weight to the pooled analysis due to reporting much
smaller standard deviations. Sensitivity analysis with a random-
effects model results in reduced weighting for that study, and in-
creased the size of the CI such that the lower confidence interval
included no difference (MD 4.76, 95% CI −0.86 to 10.39; par-
ticipants = 120; studies = 2).
Hossein 2016 reported a significantly greater per cent predicted
PEF in theMgSO andβ -agonist and ipratropium group at 20
minutes (MD 6.90, 95% CI 1.63 to 12.17) but an important be-
tween-group difference was not found when 60 minute data were
combined with 60 minute data from the large Goodacre 2013 trial
(MD 0.05, 95% CI −2.33 to 2.42; participants = 636; studies
= 2; I² = 67%). A random-effects model substantially increases
imprecision, and the effect estimate remains inconclusive. The
Goodacre results taken individually did not demonstrate an impor-
tant between-group difference (MD −0.30%, 95% CI −2.71%
to 2.11%).
Alansari 2015, Ashtekar 2008 and Powell 2013 did not report this
outcome. Drobina 2006 reported that “peak flow measurements
improved over time in both groups (p < 0.001). The addition
of aerosolized magnesium sulfate did not result in a statistically
significant increase in either the maximum or the average peak
flow over time (p = 0.279 and p = 0.399, respectively).” As this
research is only available in abstract form, it is unclear how many
participants were in each group and no data were reported to
include in the meta-analysis.
Clinical severity scores
Powell 2013 reported a lower (therefore better) Yung asthma sever-
ity score (ASS) in children receiving MgSO and β -agonist
and ipratropium compared to placebo (saline) and β -agonist
and ipratropium at 60 minutes (MD −0.23, 95% CI −0.48 to
0.02; participants = 472). The minimal important difference on
this nine point scale is not known, but in Powell 2013 it was re-
garded as 0.5 by the trial steering group. Goodacre 2013 reported
no significant difference in the change in dyspnoea visual analogue
scale between the groups at 60 (MD 3.10, 95% CI−0.53 to 6.73;
participants = 658) or 120 minutes (MD 3.12, 95% CI −1.35 to
7.59; participants = 619). The minimal important difference on
the 100 mm scale used in Goodacre 2013 is thought to be 22 mm.
When the ’60minute’ data from each study are combined using an
SMD analysis there is no between-group difference (SMD 0.01,
95% CI −0.11 to 0.12; participants = 1130; studies = 2) but a
high level of heterogeneity (I² = 83%). As the studies were of a
similar size and weight in this analysis, a random-effects model
has little impact on the effect estimates, although the confidence
interval is widened.
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Ashtekar 2008 reported that there was no significant difference
between the median area under the curve of ASS of the MgSO
compared with the placebo-treated group (1530 versus 1355).
Of note: Powell 2013 performed subgroup analysis for asthma
severity score, investigating whether participants with a more se-
vere asthma exacerbation or an exacerbation of shorter duration
derivedmore benefit. Although not powered to detect a difference,
the study results support the hypothesis that children with more
severe exacerbations and children with shorter duration of symp-
toms prior to presentation benefit more from inhaled MgSO as
measured using the Yung asthma severity score.
Admission to hospital
Gallegos-Solórzano 2010 reported admissions to the emergency
department and the general ward; Goodacre 2013 reported ad-
missions to hospital, HDU and ICU; and Powell 2013 reported
admissions to PICU/HDU or intubation.
Pooled results for adults and children for admissions from the
emergency department at initial presentation suggests that admis-
sions are decreased in those receiving MgSO , β -agonist and
ipratropium compared to placebo (saline), β -agonist and ipra-
tropium (RR 0.95, 95% CI 0.91 to 1.00; participants = 1308;
studies = 4; I² = 52%) but the upper confidence interval reaches no
difference (Analysis 1.4). The overall risk of admission was 82%
on placebo which translates into a 78% risk of admission (95%
CI 75% to 82%) with nebulised magnesium (Figure 3, Summary
of findings for the main comparison). The RR is the same if a
random-effects model is used, but the result is less precise (RR
0.95, 95% CI 0.87 to 1.05).
Figure 3. In the control group 82 people out of 100 had hospital admission , compared to 78 (95% CI 75 to
82) out of 100 for the active treatment group.
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Gallegos-Solórzano 2010, an adult study, also reported admission
to the emergency department (RR 0.38, 95% CI 0.16 to 0.94;
participants = 60).
Goodacre 2013 and Gallegos-Solórzano 2010, both adult studies,
reported on readmission after initial attendance (up to 7 days in
Goodacre 2013; time point unclear in Gallegos-Solórzano 2010).
There was no significant difference in admission rates between the
two groups, but the result is imprecise (RR 1.80, 95% CI 0.84 to
3.87; participants = 750; studies = 2; I² = 37%, Analysis 1.6).
Goodacre 2013 did not detect a between-group difference for ei-
therHDU admission (RR 1.19, 95%CI 0.66 to 2.13; participants
= 690) or ICU (RR 1.94, 95%CI 0.66 to 5.73; participants = 690)
but events were infrequent and both results inconclusive (Analysis
1.5). Similarly Powell 2013, a study in children, reportedHDU or
ICU admissions/intubations and did not detect a between-group
difference (RR 1.48, 95% CI 0.79 to 2.79; participants = 505).
Duration of symptoms
Not reported.
Vital signs
Hossein 2016 andGoodacre 2013 reported on vital signs at various
time points. For this update, we chose to present the 60-minute
time point in the meta-analysis. There are concerns that adminis-
tration of MgSO may lead to an unwanted drop in blood pres-
sure. Goodacre 2013 reported a significantly higher (therefore bet-
ter in this context) diastolic bloodpressure in participants receiving
MgSO and β -agonist and ipratropium compared to placebo
and β -agonist and ipratropium at 60 minutes (MD 2.40, 95%
CI 0.29 to 4.51; participants = 674), but this difference is un-
likely to be clinically meaningful (Analysis 1.10). There was no
significant difference in respiratory rate, heart rate or systolic and
diastolic blood pressure at any other time point. Similarly there
was no significant difference in the change in vital signs between
groups at 60 or 120 minutes (Goodacre 2013; data not shown).
Drobina 2006 stated that vital signs were measured in the confer-
ence abstract but data were not reported.
Adverse events
Four studies including 2067 participants reported adverse events
(Goodacre 2013; Powell 2013; Alansari 2015; Hossein 2016).
During admission, more serious adverse events were reported in
the placebo group compared to the MgSO group, but only one
of the two studies reporting this outcome contributed events and
the confidence interval includes no difference (RD −0.03, 95%
CI−0.06 to−0.00; participants = 557; studies = 2; I² = 0%; Anal-
ysis 1.11). There was no significant difference in adverse events
between groups for any adverse event (RD 0.01, 95% CI −0.03
to 0.05; participants = 1197; studies = 2; I² = 0%; Analysis 1.12).
Goodacre 2013 reported a significantly higher ’all adverse event’
rate within 30 days of primary attendance for those participants
receivingMgSO and β -agonist and ipratropium compared to
placebo (saline) and β -agonist and ipratropium (RD 0.06, 95%
CI 0.01 to 0.11; participants = 690; Analysis 1.14) but there was
no difference in serious adverse events (Analysis 1.13). Hossein
2016 reported no serious adverse events in either group in the first
60 minutes of treatment.
Both Goodacre 2013 and Powell 2013 reported hypotension and
flushing but did not detect a significant between-group difference
for either outcome (Analysis 1.15; Analysis 1.16).
Ashtekar 2008 reported that one child had a transiently low blood
pressure and another had tingling of the fingers; both received
nebulised MgSO . Drobina 2006 reported that there were no
significant side effects noted in either treatment group, but did
not report data. Gaur 2008 did not report adverse effects.
Gallegos-Solórzano 2010 reported that the most common adverse
reaction associated with MgSO was a dry and bitter mouth, but
no other side effect was associated with treatment. Electrocardio-
graphy (ECG) was abnormal in some participants (43% versus
36%): most commonly, sinus tachycardia (40% versus 36%). One
person in theMgSO group developed supraventricular extrasys-
tole that did not require additional management. One from each
group reported dizziness.
MgSO with β -agonist versus placebo (saline) and
β -agonist (comparison 2)
Pulmonary function
Eleven studies involving 589 participants reported at least one
measure of lung function (Nannini 2000; Abreu-Gonzalez 2002;
Bessmertny 2002; Hughes 2003; Mahajan 2004; Kokturk 2005;
Aggarwal 2006; Ahmed 2013; Badawy 2014; Mohammedzadeh
2014; Sarhan 2016).
Five studies reported per cent predicted FEV1; two at 120 minutes
(Badawy 2014; Sarhan 2016), two at 60 minutes (Bessmertny
2002; Hughes 2003) and one at 20 minutes (Mahajan 2004).
Due to our concerns about potential baseline imbalance and the
population recruited in Badawy 2014 (all pregnant women) we
chose not to include this study in the analysis.
Pulmonary function based on per cent predicted FEV1 was im-
proved in those who received MgSO and a β -agonist com-
pared to β -agonist and placebo, but the confidence interval in-
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cludes no difference (MD 3.34, 95% CI −1.58 to 8.26; partic-
ipants = 208; studies = 4), with moderate between-study hetero-
geneity identified (I² = 43%). We did not detect a difference be-
tween adults and children, but only one study involving children
contributed to the analysis. We were only able to present sub-
grouping based on severity at presentation with three studies as
we were unable to characterise severity in Sarhan 2016. Results
suggest the combination ofMgSO and salbutamol may be more
beneficial in people with a more severe exacerbation (FEV1 < 50%
predicted) but the test for subgroup difference was negative (I² =
51.8%, P = 0.15). Badawy 2014 reports significantly higher post-
treatment per cent predicted FEV1 in pregnant women receiv-
ing MgSO in addition to salbutamol compared to salbutamol
alone; end-point scores were 56.31% (SD 8.25) in the interven-
tion group compared to 32.68% (SD 7.15) (P < 0.001, 30 partic-
ipants), but baseline FEV1 in each group was not measured.
Six studies reported peak expiratory flow rate (PEF): one at 20
minutes (Nannini 2000), two at 60 minutes (Aggarwal 2006;
Mohammedzadeh 2014), two at 120 minutes (Badawy 2014;
Sarhan 2016), one at discharge (Kokturk 2005). Where studies
reported at more than one time point we have extracted and pre-
sented the closest time point to 60 minutes. We excluded Badawy
2014 due to the reasons given above and Kokturk 2005 due to the
incompatible time point. We have not pooled adults and children
in this analysis. In adults, there was small improvement in PEF
compared to the control group, but the confidence interval in-
cludes no difference (MD 11.91 L/min, 95% CI−4.12 to 27.95,
participants 155, studies 3, I² = 13%, Analysis 2.3). A similar
small and imprecise effect was seen in Mohammedzadeh 2014,
the study involving children: MD 11.90 L/min, 95% CI −6.86
to 30.66, participants 80. Mohammedzadeh 2014 also reports a
change frombaseline “adjusted%PEF”, which favours the combi-
nation of MgSO and salbutamol compared to salbutamol alone
(MD 6.70, 95% CI 3.80 to 9.60; data not displayed). Kokturk
2005 reported “both groups displayed comparable improvement
in PEF (%) and clinical scores over 120 min” and displayed results
graphically. Discharge mean (SD) per cent predicted PEFwas sim-
ilar in both groups (71.18 (11.55) and 70.50 (12.34)).
One study (Ahmed 2013; an abstract) reported “the percentage
increase in peak flow” at 10 and 20 minutes, but the lack of clarity
about whether this was a per cent change in the absolute values
or a change in the per cent predicted meant we could not include
data in the analyses. The study reported a greater improvement in
the intervention group compared to the control group at both 10
and 20 minutes (20 (SD 4) vs 13 (3) at 10 minutes; and 35 (7) vs
24 (6) at 20 minutes).
Abreu-Gonzalez 2002 (n = 24), also a conference abstract, selec-
tively reports improvement in PEF at 30 minutes for people in the
β -agonist and MgSO group compared to the placebo plus
β -agonist group and improvement in FEV1 at 45 minutes for
those in the β -agonist alone with placebo group compared to
the β -agonist and MgSO group.
Clinical severity score
Four studies involving 575 participants reported clinical severity
scores with enough detail for data extraction (Mohammedzadeh
2014; Alansari 2015; Sarhan 2016; Turker 2017), but we did not
perform meta-analysis. Pulmonary index score was significantly
lower (therefore better) for those receiving MgSO and β -
agonist compared to β -agonist and placebo at 90 minutes in
Mohammedzadeh 2014 (MD −0.90, 95% CI −1.43 to −0.37,
participants = 80; ) but not at other time points. Sarhan 2016
reported no significant difference in change in Fischl index at
two hours between the two groups (MD −0.10, 95% CI −1.22
to 1.02; participants = 20; studies = 1). Alansari 2015 reported
PRAM asthma severity score at seven time points (from four to
48 hours). PRAM was significantly lower (therefore better) for
those receiving placebo (saline) and β -agonist and ipratropium
compared to MgSO and β -agonist and ipratropium at the
earliest time point (4 hours; MD −0.4, 95% CI −0.7 to −0.01;
P = 0.05; participants = 365;) but not at later time points. Turker
2017 measured the modified pulmonary index score at 20, 40 and
120 minutes post baseline but it was only possible to extract data
at 120 minutes; no between-group difference was identified (MD
0.38, 95% CI −0.25 to 1.01; participants = 100; studies = 1).
Kokturk 2005 reported that both groups displayed comparable
improvement in clinical scores over 120 minutes. Khashabi 2008
reported a non-significant difference in respiratory distress scores,
but it is not clear which score was used and the number of par-
ticipants in each group is not clear. The author was contacted for
further information before the 2012 update but no response was
received.
Admission to hospital
Six studies involving 375 participants reported admissions for
MgSO and β -agonist compared to β -agonist and placebo
(Nannini 2000; Hughes 2003; Mahajan 2004; Kokturk 2005;
Aggarwal 2006; Turker 2017). Although there was a reduction in
the risk of admission for people receiving the MgSO interven-
tion, the confidence interval includes no difference (risk ratio 0.78,
95% CI 0.52 to 1.15; participants = 375; studies = 6; I² = 0%). It
should be noted that this analysis is dominated by evidence from
adult studies. As we did not detect any statistical heterogeneity in
the analysis we did not perform our prespecified subgroup analy-
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ses. One study in children reported that one child from each group
required admission/re-admission in the two weeks after discharge
(Alansari 2015).
Vital signs
Three studies including 190 participants reported heart rate at
120 minutes (Aggarwal 2006; Badawy 2014; Sarhan 2016). As
previously, we have not included Badawy 2014 in the analysis and
combining the remaining two studies resulted in such substantial
heterogeneity (I² = 82%) that we did not perform meta-analysis
(Analysis 2.5). Participants receiving MgSO and β -agonist
had a slightly lower (therefore better) heart rate at 120 minutes
compared to those receiving β -agonist and placebo in Aggarwal
2006 (MD −2.70, 95% CI −6.15 to 0.75; participants = 100),
but the opposite effect was seen in Sarhan 2016 (MD 22.60, 95%
CI 1.61 to 43.59; participants = 20). Badawy 2014 reported aMD
of −25.46 (95% CI −28.38 to −22.54) favouring the MgSO
group.
There was no significant difference between the two groups in
systolic or diastolic blood pressure or respiratory rate in the studies
reporting these outcomes.
Adverse events
Serious adverse events were reported by five studies including 243
participants (Nannini 2000; Bessmertny 2002; Hughes 2003;
Mahajan 2004; Sarhan 2016). No serious events occurred in any
of the studies (Analysis 2.9).
Three studies reported on mild-moderate adverse events (Nannini
2000; Bessmertny 2002; Aggarwal 2006); and two reported all
adverse events (Ahmed 2013; Alansari 2015). There was no signif-
icant difference in those experiencing one or more events between
the two groups (RD −0.01, 95% CI −0.05 to 0.03; participants
= 694; studies = 5; I² = 0%; Analysis 2.10); and no difference
detected between adults and children.
Turker 2017 reports narratively that “no side effect caused by
magnesium was observed in any of the patients in the study”; this
data has not been included in the forest plots.
Aggarwal 2006 reported that tremor was the same in both groups.
Khashabi 2008 reported no side effects but it is not clear howmany
participants were in each group, so their data were not included in
this analysis. Kokturk 2005 reported that two participants in the
MgSO group and four in the placebo group required additional
therapy. Two participants developed transient hypotension after
receiving MgSO and β -agonist. No one needed nebulisation
to be withheld. One participant in the placebo group suffered pal-
pitations after the second salbutamol nebulisation. No other side
effects were reported. Alansari 2015 reported that no participants
experienced hypotension; one participant in the placebo group
had excessive cough after the first nebulisation and was withdrawn
by his parents; one participant in the MgSO group experienced
chest tightness and facial rash after the third nebulisation (both
resolved after 30 minutes); and one placebo group participant re-
quired paediatric ICU admission for refractory status asthmaticus.
MgSO versus β -agonist alone (comparison 3)
Pulmonary function
Four studies involving 133 participants reported PEF, but due
to the range of time points and ways of reporting the outcome
we have not presented the results on a forest plot. Mangat 1998
found no significant difference in % predicted PEF for MgSO
alone compared with β -agonist alone at 60 minutes (MD 4.20,
95% CI −12.29 to 20.69; participants = 33). Neki 2006 shows
a significant advantage for β -agonist alone but the time point
reported is unclear (MD−50 L/min, 95% CI−67.83 to−32.17;
participants = 4). Meral 1996 reported the mean improvement
per group in PEFR (%) at five minutes, favouring the β -agonist
group (MD −36.77, 95% CI −61.26 to −12.28; participants =
40). Sarhan 2016 reported change in per cent predicted PEF and
found no significant difference between groups (MD−1.70, 95%
CI −8.45 to 5.05; participants = 20).
Clinical severity score
The Fischl index (a composite of vital signs, PEF and clinical fea-
tures ranging from 0 to 7 with scores > 4 indicating acute severe
asthma) was reported in three studies (Mangat 1998; Neki 2006;
Sarhan 2016); and theDavies, Leffert,Drabous score (a composite
measure of retraction, nasal flaring, cyanosis and wheeze) in one
study (Meral 1996). We pooled the results for studies reporting
the Fischl Index, which suggests no significant between-group dif-
ference (MD −0.13, 95% CI −0.62 to 0.36; participants = 93;
studies = 3; I² = 0%).
Meral 1996 reported the maximum clinical severity score in the
first hour (MD −3.20; 95% CI −17.62 to 11.22; participants =
40).
Admission to hospital
There was no significant difference in risk of admission between
those receiving MgSO alone compared with β -agonist alone
(RR 0.53, 95% CI 0.05 to 5.31; participants = 33, studies = 1;
Analysis 3.2); however, the wide confidence interval indicates, due
to there being few events in a small trial, that equivalence cannot be
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claimed. With a single trial contributing data (Mangat 1998), no
additional analyses were possible. Three studies did not appear to
measure or report this outcome (Meral 1996; Neki 2006; Sarhan
2016).
Vital signs
Sarhan 2016 reported a significantly lower (therefore better) mean
heart rate in people receiving β -agonist alone compared to
MgSO alone (MD 21.20, 95% CI 0.17 to 42.23; participants
= 20). Respiratory rate was reported as significantly lower (there-
fore better) in those receiving MgSO alone compared to β -
agonist alone (MD−2.40, 95% CI−3.91 to−0.89; participants
= 60; studies = 2; I² = 0%)(Neki 2006; Sarhan 2016). There was
no significant difference in systolic or diastolic blood pressure be-
tween those receiving MgSO alone compared with β -agonist
alone in the one study which reported this (Analysis 3.5; Analysis
3.6).Two studies did not appear to measure or report these out-
comes (Meral 1996; Mangat 1998).
Adverse events
Two studies reported that there were no serious adverse events in
either arm (participants = 53; studies = 2) (Mangat 1998; Sarhan
2016). One study reported mild to moderate adverse events and
no difference was detected between groups (RD −0.17, 95% CI
−0.41 to 0.06; participants = 33; Analysis 3.8). Meral 1996 also
reported that there were no adverse events in either group. One
study did not report adverse events (Neki 2006).
Reporting biases
Too few studies were included in any meta-analysis to produce a
funnel plot. However, the impact of publication bias was likely
limited through a thorough search strategy.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
MgSO + SABA compared to SABA in the treatment of acute asthma
Patient or population: adults and children with acute exacerbat ion of asthma
Setting: emergency department/ inpat ient
Intervention: MgSO + SABA
Comparison: SABA
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with SABA Risk with MgSO4 +
SABA
Pulmonary funct ion %
predicted FEV1
(20 minutes to 2 to 3 h)
The mean pulmonary
funct ion % predicted
FEV1 was 56.55%
% predicted FEV1 was
3.34% higher
(1.58 lower to 8.26
higher)
- 208
(4 RCTs)
⊕⊕©©
LOW 12
Adults vs children test
for subgroup dif fer-
ence: P = 0.35, I² = 0%
Severe vs moderate
asthma exacerbat ion
test for subgroup dif fer-
ence: P = 0.15, I² = 51.
8% (favouring a greater
ef fect in the more se-
vere subgroup)
Pulmonary funct ion
PEF L/ min - Adults
(20 minutes to 2 to 3 h)
The mean pulmonary
funct ion PEF was 233
L/ min
PEF was 11.91 L/ m in
higher
(4.12 lower to 27.95
higher)
- 155
(3 RCTs)
⊕⊕©©
LOW 12
Pulmonary funct ion
PEF L/ min - Children
(60 minutes)
The mean pulmonary
funct ion PEF was 143.5
PEF was 11.9 L/ m in
higher
(6.86 lower to 30.66
higher)
- 80
(1 RCT)
⊕⊕©©
LOW 23
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Admission to hospital
at init ial presentat ion
202 per 1000 158 per 1000 (105 to
233)
RR 0.78, (0.52 to 1.15) 375
(6 RCTs)
⊕⊕©©
LOW 12
Adults vs children test
for subgroup dif fer-
ence: P = 0.35, I² = 0%
Serious adverse events
(During ED/ hospital ad-
mission)
Not est imable Not est imable. See
comment
- 243
(5 RCTs)
⊕⊕©©
LOW 14
Risk dif ference: 0.00
(95% CI −0.04 to 0.04)
No events reported
Any adverse events
(During ED/ hospital ad-
mission)
107 per 1000 Not est imable. See
comment
- 694
(5 RCTs)
⊕⊕©©
LOW 12
Risk dif ference: −0.01
(95% CI −0.05 to 0.03)
Adults vs children test
for subgroup dif fer-
ence: P = 0.77, I² = 0%
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; ED: emergency department; FEV1 : f orced expiratory volume in 1 second; OR: Odds rat io; PEF: peak expiratory f low; RD: risk dif f erence; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Several studies were at unclear or high risk of bias in one or more domain (−1 study lim itat ions)
2 Conf idence intervals include both possible harm and benef it of the intervent ion (−1 imprecision)
3 Study at unclear risk of bias in several domains (−1 study lim itat ions)
4 No events reported but less than 250 part icipants in total. Risk dif f erence conf idence intervals include a possible important
harm or benef it of the intervent ion (−1 imprecision)
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MgSO compared to SABA in the treatment of acute asthma
Patient or population: adults and children with acute exacerbat ion of asthma
Setting: emergency department/ inpat ient
Intervention: MgSO
Comparison: SABA
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with SABA Risk with MgSO4
Lung funct ion Reported narrat ively in
text
Clinical severity score -
Fischl index
(120 minutes)
The Fischl index score
was 2.1
Fischl index score 0.13
lower
(0.62 lower to 0.36
higher)
- 93
(3 RCTs)
⊕©©©
VERY LOW 123
Time point 120 minutes
in 2 studies and unclear
in the third study
Wide range of control
group scores (0.3, 0.
76 and 4.81). Scale
out of 7 with higher
score indicat ing more
severe symptoms. 4.81
reported in study with
unclear t ime point
Admission to hospital
at init ial presentat ion
118 per 1000 62 per 1000
(6 to 625)
RR 0.53
(0.05 to 5.31)
33
(1 RCT)
⊕©©©
VERY LOW 45
Serious adverse events
(During ED/ hospital ad-
mission)
Not est imable Not est imable. See
comment
53
(2 RCTs)
⊕⊕©©
LOW 16
Risk dif ference: 0.00
(95% CI −0.10 to 0.10)
No events reported
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Several studies at unclear or high risk of bias in one or more domains (−1 study lim itat ions)
2 Conf idence intervals include both possible harm and benef it of the intervent ion (−1 imprecision)
3 Time-point for measurement unclear in one study (−1 indirectness)
4 Study at unclear risk of bias in several domains (−1 study lim itat ions)
5 One small study. Conf idence intervals include appreciable harm or benef it of the intervent ion (−2 imprecision)
6 Two small studies. No events reported. Risk dif ference conf idence intervals include appreciable harm or benef it of the
intervent ion (−1 for imprecision)
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D I S C U S S I O N
Summary of main results
This systematic review summarises evidence from twenty-four tri-
als including 2807 randomised participants with acute exacerba-
tions of asthma. The most recent update added three new large
trials (Goodacre 2013; Powell 2013; Alansari 2015), as well as sev-
eral small trials. Overall, the results are conflicting with some, gen-
erally small, benefits seen of adding MgSO to standard therapy
for an exacerbation of asthma. The larger and more recent studies
typically show a smaller effect than some of the older/smaller stud-
ies. Serious adverse events were rare across all four comparisons,
suggesting the treatment is generally well tolerated in people expe-
riencing moderate to severe exacerbations of asthma. Differences
between studies in the populations, outcomes reported and time
points limited the number of meta-analyses performed.
Comparison 1: MgSO and β -agonist and
ipratropium versus placebo and β -agonist and
ipratropium
We included seven studies in this comparison and were able to
extract data on lung function, clinical severity scores, admissions to
hospital, vital signs and adverse events. Although some individual
studies reported improvement in lung function indices favouring
the intervention group, results were inconsistent and may not be
clinically relevant overall. The largest study reporting this outcome
reported no between-group difference at 60 minutes (Goodacre
2013).
Similarly, clinical severity scores typically did not demonstrate a
benefit of the intervention compared to control. Powell 2013, a
large study in children, reported a benefit at 60 minutes using the
Yung asthma severity score, but the mean difference is unlikely to
be clinically important. Admissions to hospital at initial presenta-
tion may be reduced by the addition of inhaled magnesium sul-
fate, but the upper end of the confidence interval includes no dif-
ference (RR 0.95, 95% CI 0.91 to 1.00) and it is hard to compare
the studies as in Powell 2013 and Goodacre 2013 almost everyone
was admitted to hospital, while in the smaller studies a smaller
proportion of participants were admitted.
No difference was detected for re-admissions or escalation of care
to ITU/HDU, but events were generally rare. Administration
of magnesium sulfate has been associated with hypotension and
Goodacre 2013 reported a slightly higher diastolic blood pres-
sure in the control group, but the effect size was small (MD 2.40
mmHg, 95% CI 0.29 to 4.51). No other between-group differ-
ences were detected in the studies reporting vital signs. Finally,
serious adverse events during admission were rare and only one
study contributed to this analysis. There was no difference be-
tween groups for all adverse events during admission (RD 0.01,
95% CI −0.03 to 0.05). Goodacre 2013 reported a lower risk of
all adverse events in the 30 days after admission in the placebo
group, but no difference in serious adverse events (around 10%
of people experience a serious adverse event and 15% an adverse
event).
Comparison 2: MgSO with β -agonist versus β -
agonist
We included 15 studies in this comparison and were able to ex-
tract data on lung function, clinical severity scores, admissions
to hospital, vital signs and adverse events. While some individual
studies reported improvement in lung function indices favouring
the intervention group, none of the pooled results showed a clini-
cally meaningful benefit as measured by FEV1 or PEFR. Clinical
severity scores were reported using a number of different scales and
at different time points, but no consistent difference between the
two groups was identified. Pooled results for hospital admission
favoured the combination of MgSO and β -agonist, but the
confidence interval includes the possibility of admissions increas-
ing in the intervention group (RR 0.78, 95% CI 0.52 to 1.15).
Few studies reported vital signs and of those that did, none de-
tected a significant between-group difference, with results often
imprecise. There were no serious adverse events reported by any
of the included studies and no between-group difference for all
adverse events (RD −0.01, 95% CI −0.05 to 0.03).
Comparison 3: MgSO versus β -agonist alone
We included five studies in this comparison and were able to ex-
tract data on lung function, clinical severity scores, admissions to
hospital, vital signs and adverse events. As the evidence for use of
β -agonists in acute asthma is well-established this could be con-
sidered a historical comparison, no longer in keeping with current
clinical practice. Two studies reported a benefit in lung function
of β -agonist over MgSO alone and two studies reported no
difference; we did not pool these results. No between-group dif-
ference was detected for clinical severity scores (Fischl index) but
results are based on only a few small studies, which measured at
different time points (MD −0.13, 95% CI −0.62 to 0.36; par-
ticipants = 93). Admissions to hospital were only reported by one
small study and events were rare, leading to an uncertain result.
Effects on vital signs were inconsistent; one small study reported
lower heart rate in the β -agonist group, while pooled results
from two studies found a lower respiratory rate in the MgSO
group. No serious adverse events were reported in any of the stud-
ies in this comparison; one small study reported mild to moderate
adverse events but the result is imprecise.
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Overall completeness and applicability of
evidence
Comparisons 1 and 2, in which MgSO was combined with
other bronchodilators, are themost consistent with current clinical
guidance, and therefore most applicable to practice (BTS/SIGN
2016; GINA 2017). Comparison 3, in which MgSO was the
only inhaled bronchodilator given during the intervention period
in one arm, could be considered a more historical comparison.
Given the strong evidence of the efficacy of beta-agonists in acute
asthma, it is unlikely that studies with this design would receive
ethical approval in many settings.
Within comparisons 1 and 2, populations, interventions, out-
comes and time points were heterogeneous, which limited the
number of meta-analyses performed and therefore the conclu-
sions reached. However three large, well-powered studies of high
methodological quality were added to this 2017 update and over-
all did not demonstrate a substantial benefit of the addition of in-
haledMgSO to standard therapy (Goodacre 2013; Powell 2013;
Alansari 2015), although modest benefits were seen in some in-
dividual studies and meta-analyses. However, we were not able to
fully implement our planned subgroup analysis for severity and
thus there remains uncertainty about whether those with more
severe exacerbations derive greater benefit.
The included studies used a variety of different dosing regimens
for MgSO , including different numbers and frequency of doses
and differentMgSO formulations. The precise regimen was not
described in all included studies (Table 3). A limitation of this
review is that we did not attempt to subgroup studies according to
dosing regimen used. It is possible that this is an important effect
modifier which may require further investigation. Also, we have
not attempted to explore the cost-effectiveness of using inhaled
MgSO ; any clinical benefits need to be considered in the context
of possible increased costs associated with deliveringMgSO and
monitoring patients during treatment.
We chose lung function (FEV1 and PEFR) as the primary out-
come in this review. Lung function may be considered a surro-
gate outcome in asthma and does not always correlate well with a
patient’s symptoms, quality of life and asthma control (Carranza
Rosenzweig 2004; Aburuz 2005). In an acute setting, however,
lung function - particularly peak flow - is frequently used to guide
management and assess response to therapy; and validated patient-
reported outcomes such as the AsthmaControl Questionnaire and
Asthma Quality of Life Questionnaire have limited applicability
during acute exacerbations.
Other uncertainties in the findings are introduced by the lack
of consistency between settings in deciding whether, and if so
when, to admit patients from the emergency department into the
hospital. There were marked differences between studies in terms
of the proportion of patients admitted; this may reflect different
practices in different hospitals, varied exacerbation severity in those
recruited and differences between practices in paediatric and adult
populations. Although these variations should be accounted for in
the randomisation process within each trial, it introduces clinical
heterogeneity into our meta-analyses and further complicates the
interpretation of the evidence.
Finally, adverse events were not consistently reported by all studies.
However, we were able to extract data extracted from the more re-
cent larger studies and the combined evidence suggest that inhaled
MgSO is unlikely to be associated with an important increase
in serious adverse events in the populations studied - it should be
noted that events were rare.
Quality of the evidence
Our confidence in the results presented in this review ranges from
high to very low, but overall most of the evidence was rated as being
of low or very low quality. This means the true effect may be sub-
stantially different from the estimate of the effect presented. Please
see Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3 for full details of our GRADE
assessments. Our confidence was reduced by a number of different
considerations.
Most studies were at unclear or high risk of bias in multiple do-
mains; only four studies were considered to be at low risk of bias
in all domains (Aggarwal 2006; Goodacre 2013; Powell 2013;
Alansari 2015). Many studies did not clearly report their methods
of randomisation or allocation. In some studies it was not clear
who was masked to treatment group assignment and we had con-
cerns about attrition bias and selective reporting in multiple stud-
ies. We downgraded for study limitations when we were judged
that a study about which we had important methodological con-
cerns contributed sufficient weight to analysis to potentially affect
the overall estimate.
Imprecision was also a problem in many of the meta-analyses with
sample sizes too small and events too few to rule out potential im-
portant harm or benefit of the intervention. This was a problem in
the lung function, hospitalisation and adverse event analyses. Un-
explained statistical heterogeneity was encountered less frequently
but this may be a result of us being unable to perform meta-anal-
yses with substantial numbers of studies contributing data. Indi-
rectness was not thought to be a problem in any of the outcomes
to which we applied GRADE and we did not have sufficient stud-
ies in any one analysis to formally assess publication bias using a
funnel plot.
Potential biases in the review process
Publication bias may have influenced the result of this meta-anal-
ysis. For example, by missing unpublished negative trials we may
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be over-estimating the effect of MgSO treatment. In order to
reduce bias, however, a comprehensive and systematic search of
the published and unpublished literature for potentially relevant
studies was conducted and we have recently updated it. This was
followed by our attempts to contact corresponding and first au-
thors. However, we recognise that unpublished data may exist.
We conducted our review in accordance with Cochrane methods
and have detailed changes between the protocol and the review
in Differences between protocol and review section. One such
difference, which may have introduced bias, is the selection of
the ’60 minute’ time point for reporting outcomes. Many studies
reported outcome at multiple time points and for consistency we
selected the outcome closest to 60 minutes from baseline for meta-
analysis. We chose this time point by consensus to maximise the
homogeneity of pooled results and because this was identified as a
clinically relevant time point for decision making about treatment
escalation (i.e. there would be an expectation thatmost patients are
showing a response to treatment with an hour). It is conceivable
that choice of a different time point might have led to different
conclusions, especially for the lung function and clinical severity
score indices, which may be more susceptible to fluctuations over
short periods of time.
Agreements and disagreements with other
studies or reviews
The conclusions in this updated Cochrane Review are broadly
consistent with the previous version of the review (Powell 2012):
that there may be some modest benefits associated with addition
of magnesium sulfate (MgSO ) to standard therapy for acute
asthma.However, the addition of several large and well-conducted
studies suggests that there is unlikely to be a substantial additional
benefit associatedwith the addition of inhaledMgSO . Although
we now have more data in children and the effect appears to be
similar to that seen in adults, formal subgrouping by age was not
always possible due to lack of sufficient data and between-trial
heterogeneity.
To our knowledge, no other systematic review has included as
many primary studies as the present review and therefore conclu-
sions are not entirely comparable and findings are somewhat con-
flicting. Overall, systematic reviews published to date have failed
to demonstrate a conclusive benefit of inhaled magnesium sulfate
in acute asthma and have suggested the role of the intervention
remains unclear. For example, a systematic review published in
2006 included six studies, all of which are included in the present
review. Despite some evidence of benefit, the authors were unable
to reach conclusions due to lack of evidence and stated that the
role of inhaled magnesium sulfate remains unclear. Similarly, a
2005 review also included six studies and concluded that nebulised
MgSO may confer some benefits in terms of pulmonary func-
tion and hospital admission, but called for more research (Blitz
2005). These findings are also consistent with the systematic re-
view by Mohammed 2007.
More recently, a 2016 systematic review summarised the literature
for both inhaled and intravenous magnesium sulfate in children
with acute asthma (Su 2017). The review included four studies
of nebulised magnesium sulfate in children, three of which we
included and one which we excluded as it was a study of metha-
choline challenge test in stable asthma.The review concluded there
was no impact on hospital admission or lung function. Similarly,
a 2012 systematic review in adults included six studies of nebu-
lised MgSO (all of which are included in the present review)
and concluded that there was insufficient evidence to recommend
the use of this intervention (Song 2012). A 2016 review identi-
fied 10 relevant trials and concluded “adding nebulized MgSO
neither improved pulmonary function nor reduced the number
of hospital admissions in adult patients with acute asthma” (Ling
2016). Finally, a 2013 review of both intravenous and inhaled
magnesium sulfate suggested that there is a benefit for adults in
terms of hospital admissions and lung function, but no benefit
seen in children (Shan 2013). However, this study included only
nine trials of inhaled magnesium sulfate, all of which are included
in the present review with the exception of one, because we did
not consider it to be an RCT.
Finally, two recent Cochrane Reviews have examined the efficacy
and safety of intravenous (IV) MgSO in adults and children
with acute asthma (Griffiths 2016; Kew 2014). The review in
adults included 14 studies, randomising over 2000 participants,
and concluded that “a single infusion of 1.2 g or 2 g IV MgSO
over 15 to 30 minutes reduces hospital admissions and improves
lung function in adults with acute asthmawho have not responded
sufficiently to oxygen, nebulised short-acting beta -agonists and
IV corticosteroids”. Limited evidence was found for other mea-
sures of benefit and safety (Kew 2014). The evidence in children
is more limited with only five studies, involving 182 children, in-
cluded in the review (Griffiths 2016). The authors conclude that
IV MgSO may reduce the need for hospital admission in chil-
dren with moderate to severe asthma exacerbations, but emphasise
the small number of trials and participants. Clinicians managing
acute asthma and considering the use of a magnesium prepara-
tion will need to choose between the inhaled and IV route; at this
time, the evidence for IV magnesium may seem more persuasive,
in keeping with guidance (BTS/SIGN 2016).
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Treatment with nebulised MgSO may result in modest addi-
tional benefits when added to inhaled β -agonists and iprat-
ropium bromide, but our confidence in the evidence is low and
there remains substantial uncertainty. The recent large, well-de-
signed trials have generally not demonstrated clinically important
benefits. NebulisedMgSO does not appear to be associated with
an increase in serious adverse events or all adverse events, but se-
rious events were rare and results lacked precision. Those with a
more severe exacerbation may experience a greater benefit but as
we were unable to implement our planned subgroup analysis for
severity this remains an area of uncertainty. Evidence regarding
the use of nebulised MgSO as an alternative to beta-agonists is
sparse and inconclusive. Given the wealth of evidence about the
use of beta-agonists in acute asthma it seems unlikely that future
trials will address this question directly.
Implications for research
Despite including 25 trials in this review update we were unable
to pool data for all outcomes of interest and this has limited the
strength of the conclusions reached. An agreement on the core
outcomes for studies in acute asthma is needed so that any acute
asthma study has the same outcomes measured - physiological,
cost and those relevant to patients. This is particularly important
in paediatric studies where lung function measurement may be
more challenging.
Placebo-controlled trials in patients not responding to standard
maximal treatment, including inhaled β -agonists and iprat-
ropium bromide and systemic steroids, may help establish if neb-
ulised MgSO has a role in acute asthma, although the accumu-
lating evidence suggests that a substantial benefit may be unlikely.
Trials comparing the safety and efficacy of inhaled MgSO to
intravenous MgSO , including an economic evaluation, are also
of interest.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abreu-Gonzalez 2002
Methods Randomised, controlled, double blind study, 2 groups.
1 centre in Tenerife.
Participants 24 patients (Intervention 13, Control 11), adults, acute asthma, moderate obstruction
Interventions Intervention: 2 mL of MgSO (isotonic) dose and 400 mcg of salbutamol (delivery
probably by MDI)
Control: 2 mL of a physiological serum of an inhaled form, 400 mcg of salbutamol
(delivery probably by MDI)
Nebuliser: no details.
Outcomes FEV1 and PEF at 0, 15, 30 45 minutes.
Notes Funding: Gobierno Autonomo Canarias.
Abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details but stated as “randomised”.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details.
Selective reporting (reporting bias) Unclear risk Abstract only and not all time points re-
ported.
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Aggarwal 2006
Methods Double blind, randomised controlled trial, parallel.
1 emergency department in India.
Participants Inclusion criteria: participants aged 13 to 60, BTS definition acute asthma (PEF and
clinical features)
Exclusion criteria: first episode ofwheeze, chronic bronchitis or emphysema, heart failure,
angina, renal failure, temperature > 38 ºC, ET tube required, no consent, pregnancy,
failure to do peak flow
Intervention: 50 randomised.
Mean age (years): 46.26 (13.96).
Men:women: 27:23.
Acute severe: 29.
Acute life threatening: 21.
Smokers: 9.
Baseline PEF: 118.6 (41.3).
Duration of attack; days (SD) 4.16 (1.69).
Control: 50 randomised.
Mean age (years): 41.00 (16.66).
Men: women: 33:17.
Acute severe: 30.
Severe life threatening: 20.
Smokers: 5.
Baseline PEF: 111.6 (43.3).
Duration of attack; days (SD) 4.28 (1.99).
Interventions Intervention: MgSO (1 mL of 500 mg/mL MgSO ) and salbutamol (1 mL of salbu-
tamol) 8 mL distilled water - 295 mOsmol/kg ×3 in an hour
Control: salbutamol 1 mL, 1.5 mL distilled water, 7.5 mL normal saline - 287 mOsmol/
kg ×3 in an hour
Treatment over 1 h; 3 nebulisers 20 minutes apart. Follow-up for 20 minutes.
Ultrasonic nebuliser.
Outcomes PEF, heart rate, systolic pressure, diastolic pressure, time in ED, blood gases (O and CO
- 0 and 120 minutes), magnesium levels (0 and 120 minutes)
Time points 0, 15, 60, 75, 120 minutes.
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Low risk Separate envelopes to ensure concealment
until inclusion (where they were kept and
whether tamper proof - not mentioned)
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Aggarwal 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The 2 researchers were blinded to the treat-
ments so measurements (normal clinical
outcomes) remained blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 50 participants both sides at beginning and
50 participants both sides completed the
study with full outcome data
Selective reporting (reporting bias) Low risk Follow-up data and longer-term outcome
data not collected. No apparent indication
of selective reporting
Ahmed 2013
Methods Randomised open controlled trial.
1 hospital in Bangladesh.
Participants Inclusion criteria: severe acute asthma.
Exclusion criteria: none stated.
120 randomised.
Intervention: 60 randomised.
Control: 60 randomised.
Interventions Intervention: salbutamol with MgSO .
Control: salbutamol with normal saline.
Outcomes PEF, respiratory rate, pulse rate, systolic, diastolic blood pressure, adverse effects
Notes Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details but states randomized.
Allocation concealment (selection bias) Unclear risk No details given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial.
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Ahmed 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear how many participants com-
pleted the trial or if any were excluded from
analysis
Selective reporting (reporting bias) Unclear risk Conference abstract. no prospective trial
registration identified, no outcome mea-
sures pre-specified
Alansari 2015
Methods Double-blind, randomised controlled trial.
1 Paediatric emergency centre, Qatar.
Participants Inclusion criteria: moderate/severe asthma exacerbation, age 2-14 years, previous diag-
nosis of asthma
Exclusion criteria: prematurity, critical illness needing ICU admission for IV bron-
chodilator, NIV or invasive ventilation, transfer to other institution, history of hypersen-
sitivity toMgSO , history of neuromuscular/cardiac/renal disease, underlying structural
lung disease, received systemic steroid/theophylline/ipratropium in prior 72 h, consol-
idation on chest XR, received IV MgSO before randomisation, prior participation in
the study, haemodynamic instability
Number randomised: 400.
Intervention: 208 randomised.
Mean age (years): 5.6 (3.1).
Male:female: 133:75.
Moderate:severe: 168:40.
Mean baseline asthma severity score: 7.6 (1.3).
Control: 192 randomised.
Mean age (years): 5.8 (3.1).
Male:female: 115:77.
Moderate:severe: 163:29.
Mean baseline asthma severity score: 7.5 (1.3).
Interventions Intervention: 800 mg MgSO (15 mL).
Control: 15 mL 0.9% NaCl.
Medication divided into 3 doses over 1 h.
Jet nebuliser.
Outcomes Time to medical readiness for discharge, mean asthma severity score (4, 8, 12, 24, 36,
48 h), mean asthma severity score at discharge, need for revisit or readmission (2 weeks)
Adverse events: chest tightness and facial rash (1; intervention group). Excessive cough
(1; control group). ICU admission (1; control group)
Notes Funding: Hamad Medical Corporation; Number: 12095/12
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Alansari 2015 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation with-
out blocks.
Allocation concealment (selection bias) Low risk Randomisation list provided to pharmacy
resulted in preparation of identical-appear-
ing sealed numbered vials
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study personnel were blinded to treat-
ment.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel were blinded to treat-
ment. The paper was not explicit re. out-
come assessors they were assumed to also
have been blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Over 90%completed the trial in both arms.
Balanced number were excluded from each
arm, with reasons given
Selective reporting (reporting bias) Low risk Prospective trial registration. All listed out-
comes are reported
Ashtekar 2008
Methods Parallel
1 Children’s Assessment Unit, 1 hospital (UHW).
Participants Inclusion criteria: age range 2 to 16 years, acute severe asthma
Exclusion criteria: chronic lung disease, congenital heart disease, unable to understand
English
17 randomised (8 boys).
Intervention: 7 completed.
Control: 10 completed.
Interventions Intervention: 2.5 mL isotonic MgSO (3 occasions at 20-minute intervals), salbutamol
and ipratropium bromide
Control: 2.5 mL isotonic saline (3 occasions at 20-minute intervals), salbutamol and
ipratropium bromide
3 dosages over 1 h: follow-up for 240 minutes.
Outcomes Asthma severity scores (ASS), the sum of wheeze, accessory muscle use and heart rate,
were computed on 6 occasions over 4 h. The primary endpoint was the area under the
curve of the ASS at the 6 time points for each child
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Ashtekar 2008 (Continued)
Notes Funding: local R and D pilot funding.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation by pharmacy at
source in ED as sequential vials (code in
pharmacy)
Allocation concealment (selection bias) Low risk As above - absolute concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial described as double blind: as above.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial described as double blind: as above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data collected for the 17 patients.
Selective reporting (reporting bias) Unclear risk Abstract only.Outcomes partially reported.
Badawy 2014
Methods Randomised controlled trial.
Outpatient department and Emergency department from 1 hospital, Egypt
Participants Inclusion criteria: pregnancy, acute exacerbation of asthma partially or not completely
controlled on routine acute asthma therapy
Exclusion criteria: congestive heart failure, history of angina, renal problems, history
suggestive of pulmonary oedema, very severe asthma (altered consciousness, respiratory
acidosis, needing intubation, arrest), any associated medical illness e.g. diabetes/hyper-
tension, fever > 38°C, inability to perform PEF
Number randomised: 60.
All participants female.
Intervention: 30 randomised.
Mean age (years): 25.7 (3.8).
Control: 30 randomised.
Mean age (years): 25.9 (4.0).
Interventions Intervention: 500 mg (1 mL) MgSO with 1 mL salbutamol solution and 8 mL 0.9%
NaCl
Control: 1 mL salbutamol solution with 9 mL 0.9% NaCl.
Treatments given over 8 minutes; max 3 sets of nebulisation 20 minutes apart
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Badawy 2014 (Continued)
Outcomes PEF, FEV1, FVC, FEV1/FVC ratio, FEF 25-75%, arterial blood pCO2, pO2 and pH,
oxygen saturations, serum potassium. Recorded at end of therapy assumed to be 2 h
from baseline
Notes Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were randomly classified into
groups comparable in socio-demographic
criteria, but no indication is given of ran-
dom sequence generation. Baseline clinical
characteristics are given, and there is no in-
dication that the groupswere balancedwith
regard to clinical criteria
Allocation concealment (selection bias) Unclear risk Participantswere randomized into 2 groups
through sealed opaque envelopes, but no
indication is given whether participants or
research personnel were aware of group al-
location
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participantswere randomized into 2 groups
through sealed opaque envelopes, but no
mention of procedures to blind personnel
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Nomention of procedures to blind person-
nel.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk On further correspondence, appropriate
exclusion criteria were applied but no in-
dication given whether excluded partici-
pants were balanced across groups, and no
dropout data were given
Selective reporting (reporting bias) High risk No prospective trial registration identified.
Primary outcome on which this trial was
powered is not stated. On further corre-
spondence, adverse event data were given
but no clinical baseline characteristics are
given
43Inhaled magnesium sulfate in the treatment of acute asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bessmertny 2002
Methods Design: parallel randomised controlled trial.
Method of randomisation: computer-generated random numbers.
Concealment of allocation: yes.
Blinding: double-blinded, placebo-controlled.
Withdrawals/dropouts: 6 (4 unable to complete spirometry, 2 inappropriate randomi-
sation)
Participants Location: 1 university hospital in Brooklyn, NY.
Participants: 74 patients, presenting to the emergency department with acute asthma
exacerbation, PEF between 40% and 80% predicted.
Exclusions: smoking history > 10 pack years, known hypersensitivity to albuterol or
MgSO , known chronic obstructive pulmonary disease, known history of renal impair-
ment, known history of cardiac dysrhythmias, congestive heart failure or angina, fever
more than 38 °C, receipt of theophylline or anti-cholinergic within 2 h of arrival to ED
Interventions Treatment: albuterol 2.5 mg/3 mL nebule followed by 384 mg isotonic MgSO every
20 min × 3.
Control: albuterol 2.5 mg/3 mL nebule followed by normal saline every 20 min × 3
Outcomes Measured FEV1 every 20 minutes for 2 h.
Adverse events: no serious adverse events noted.
Notes Funding: supported by an unrestricted educational grant from Astra Pharmaceutical
Company; no Astra Pharmaceutical Company products were used in the study. Mouth-
pieces for the spirometer were supplied at no charge from Mallinkrodt Nellcor Puritan
Bennett. Circulaire nebulizers were supplied by Westmed Inc. at a reduced rate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An assigned third party randomised partic-
ipants by means of a computer-generated
random table (1:1 randomisation) to either
the treatment or control group
Allocation concealment (selection bias) Low risk An assigned third party randomised partic-
ipants by means of a computer-generated
random table (1:1 randomisation) to either
the treatment or control group
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded, placebo-controlled. A log
of the identification number and specific
treatment of each participant was kept and
remained closed to the investigators until
the completion of the study
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Bessmertny 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded, placebo-controlled. A log
of the identification number and specific
treatment of each participant was kept and
remained closed to the investigators un-
til the completion of the study. Outcomes
were assessed every 20 minutes for 2 h
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts: 3 in each group.
Albuterol plus normal saline solution (3
unable to complete spirometry); and al-
buterol plus magnesium (2 inappropri-
ate randomisation, 1 unable to perform
spirometry)
Selective reporting (reporting bias) High risk Mean values only given for FEV1, no SDs
and the text reports that there were no sta-
tistically significant differences inFEV1be-
tween the groups. The text also states “The
analysis of continuous safety variables (BP,
pulse rate, respiratory rate, oxygen satu-
ration, and serum magnesium concentra-
tions) did not demonstrate any clinically or
statistically significant differences between
the 2 groups at any point during the study.
”
Dadhich 2005
Methods Random allocation into 3 groups parallel study.
Participants Location: 1 emergency department teaching hospital in India.
Acute severe asthma , PEF < 50%.
Group A = 24
Group B = 26
Group C = 21
Interventions Group A: salbutamol; Group B; salbutamol and MgSO ; Group C MgSO alone; no
details on dose or frequency
Outcomes FEV1, FVC, FEV1/FVC, PEF,
“Vital parameters”
Notes 2 abstracts only (the same).
Funding: not reported.
Risk of bias
45Inhaled magnesium sulfate in the treatment of acute asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dadhich 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly allocated.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details.
Selective reporting (reporting bias) Unclear risk Abstract only and no data reported ex-
cept there was a significant improvement
in groups B and C compared to group A
Drobina 2006
Methods Parallel.
Participants A total of 110 participants.
Interventions Intervention: received the control treatment with the addition
of 150 mg of MgSO (0.3 mL of 50% MgSO heptahydrate) to each nebulised dose
of medication
Control: received nebulised treatments of albuterol sulfate 0.5% (5 mg/mL) combined
with 0.5 mg of ipratropium bromide 0.02% inhalation solution (Atrovent)
Outcomes Vital signs and peak flow measurements were also assessed at the end of each treatment
(a maximum of 3 treatments) and just prior to discharge
A 24-hour follow-up call was made to each participant, during which peak flow mea-
surements were again obtained
Notes Abstract only.
Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail.
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Drobina 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Described as randomised but no detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind but no detail.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double blind but no detail.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Very limited information impossible to judge.
Selective reporting (reporting bias) Unclear risk Abstract only. Vital signs are mentioned as being recorded but
are not reported
Gallegos-Solórzano 2010
Methods RCT, parallel
Participants Inclusion criteria: adults, >18 years in the emergency dept with asthmatic crisis, FEV1
< 60% predicted
Exclusion criteria: smokers, those with ambulatory use of systemic steroids, with associ-
ated co-morbidities (neuropathy, nephropathy, heart disease, liver disease), fever at ad-
mission, use of dietary supplements with MgSO , irreversible airway obstruction (per-
sistent abnormal spirometry), near-fatal asthma, requirement of endotracheal intubation
at admission, anatomic abnormalities of the bronchial tree (bronchiectasis, tuberculosis)
, history of pulmonary or thoracic surgery, hypersensitivity to MgSO , and pregnancy
or breastfeeding
Location: National Institute of Respiratory Diseases, a tertiary care teaching hospital and
national referral centre in Mexico City
Date of study: June 2008 to March 2009.
Intervention: 60 randomised, 30 completed.
Mean age (years): 34.3 (12.4).
Men:women: 9:21.
Control: 52 randomised, 30 completed.
Mean age (years): 40.3 (11.6).
Men:women: 9:21.
Interventions Each nebulisation lasted 20 mins.
Intervention: standard nebulisation but diluted with 3 mL (333 mg) of 10% isotonic
MgSO (Magnefusin PISA, Guadalajara, Mexico; 1 g/10 mL). Also received 125 mg of
IV methylprednisolone
Control: 1 IV dose of 125 mg methylprednisolone and nebulisation with 7.5 mg of
albuterol and 1.5 mg of ipratropium bromide in 3 divided doses. Standard nebulisation
diluted in 3 mL of isotonic saline solution (SS) as placebo
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Gallegos-Solórzano 2010 (Continued)
Outcomes FEV1 post-BD (absolute in litres and as percentage of predicted), clinical improvement,
oxygen saturation, admission to the ED, admission to the asthma ward, hospital read-
missions
At 30-min post-nebulisation, patients were clinically and functionally re-evaluated. Also
evaluated at 30 days
Notes Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised.
Allocation concealment (selection bias) Low risk After randomisation, diluents were prepared by a physician out-
side the study who was not responsible for the participants’ care
and only had control of the pre-filled syringes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Both diluents are odourless, tasteless and colourless to the eye
and did not differ when transparency was measured
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The physician responsible for the participants’ care along with
the nurse and respiratory therapist were blinded to the type of
treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons given for dropouts in both groups in the CONSORT
diagram. It seems as though there are a high percentage of
dropouts but the majority are post-randomisation exclusions
based on exclusion criteria
Selective reporting (reporting bias) Low risk All outcomes stated in the Methods section are reported. Best
judgement with no access to trial protocol
Gaur 2008
Methods Parallel RCT.
Participants Age: 18 to 60 years.
Location: emergency department of a tertiary referral centre in India
Acute asthma and FEV1 < 30% predicted.
Intervention: 30.
Control: 30.
Interventions Intervention: nebulised similarly using isotonic MgSO (3 mL of 3.2 g%) as a vehicle
unsure if this is “Nebulized salbutamol and ipratropium”
Control: nebulised salbutamol and ipratropium using isotonic saline as a vehicle thrice
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at 20-min intervals
Outcomes FEV% predicted at 120 minutes, pooled discharge rate proportion of groups attaining
PEF > 60% predicted and relief in dyspnoea at 30, 60, 90, 120 min)
Notes Abstract only.
Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single blind - no further details.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Single blind - no further details.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) High risk 1 outcome partially reported and not significant. Abstract only
Goodacre 2013
Methods Double blind, randomised controlled trial.
34 emergency departments, UK.
Participants Inclusion criteria: severe (BTS/SIGN quantified) asthma attack, age ≥16 years
Exclusion criteria: life-threatening features, contraindication toMgSO , participant un-
able to give verbal/written consent, previous participation in the study; criteria amended
to exclude those who had received MgSO in the past 24 h
1109 randomised.
Intervention 1 (nebulised MgSO ): 339 randomised.
Mean age (years): 36.5 (14.8).
Men:women: 107:232.
Smokers: 98.
Mean predicted PEF (L/min): 430 (118.8).
Intervention 2 (intravenous MgSO ): 406 randomised.
Mean age (years): 35.6 (13.1).
Men:women: 130:279.
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Goodacre 2013 (Continued)
Smokers: 138.
Mean predicted PEF (L/min): 431.8 (116.9).
Control: 364 randomised.
Mean age (years): 36.4 (14.1).
Men:women: 112:252.
Smokers: 127.
Mean predicted PEF (L/min): 435.0 (110.8).
Interventions Intervention 1: 100 mL 0.9% NaCl IV and 2 mmol MgSO in 7.5 mL 0.9% NaCl
nebulised
Intervention 2: 8 mmol MgSO in 100 mL 0.9% NaCl IV and 7.5 mL 0.9% NaCl
nebulised
Control: 100 mL 0.9% NaCl IV and 7.5 mL 0.9% NaCl nebulised.
IV infusion given once over 20 mins, nebulisers given 3 times, each over 20 minutes
Outcomes Admission (4 h, 7 days); change in participant’s assessment of breathlessness via visual
analogue scale, change in PEF, heart rate, respiratory rate, BP, oxygen saturations (1, 2
h); adverse events (2 h); mortality, length of hospital stay, admission to HDU or ICU
Adverse events: treatment group 41 adverse events; control group 36 adverse events
Notes Funding: UK National Institute for Health Research Health Technology Assessment
Programme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple and blocked randomisation se-
quences used to allocate participants to
numbered treatment packs
Allocation concealment (selection bias) Low risk Allocated treatment pack numbers were
only revealed after participant details
recorded and the participant irreversibly
entered into the trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, hospital staff, and research
staff were masked to allocated treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, hospital staff, and research
staff were masked to allocated treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Over 95% of randomised participants in
each arm were included in primary analy-
sis. All participants clearly accounted for in
flowdiagram. There was an inevitable ’drop
off ’ in participants available at each time
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point for many of the secondary outcomes;
it is unclear what impact this may have had
on the results
Selective reporting (reporting bias) Low risk Prospective trial registration identified. All
primary and secondary outcomes listed in
the trial register were reported
Hossein 2016
Methods Double blind, randomised controlled trial.
2 emergency departments, Iran.
Participants Inclusion criteria: moderate/severe asthma exacerbation defined by PEFR < 40% to 69%
predicted or limiting speech/normal activity, age > 16 years
Exclusion criteria: need for immediate intubation, significant impairment of heart func-
tion, kidney or liver disease, fever > 38.3 °C, chronic lung disease, pregnancy, lactation,
pneumonia
50 randomised.
Intervention: 25 randomised.
Mean age (years): 52.4 (16.9).
Men:women: 11:14.
Acute moderate: 3.
Acute severe: 22.
Mean predicted PEF (%): 15.1 (4.7).
Control: 25 randomised.
Mean age (years): 53.9 (16.2).
Men:women: 14:11.
Acute moderate: 3.
Acute severe: 21
Mean predicted PEF (%): 14.7 (6.4).
Interventions Intervention: 3 mL MgSO solution (260 mmol/L) nebulised.
Control: 3 mL 0.9% NaCl nebulised.
Nebulised medication given every 20 to 60 minutes.
Outcomes Predicted PEFR (%), oxygen saturations, respiratory rate, dyspnoea severity index (20,
60 minutes); need for admission, serious side-effect rate (60 minutes)
Adverse effects: no “serious side-effects” reported.
Notes Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation soft-
ware used.
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Hossein 2016 (Continued)
Allocation concealment (selection bias) Unclear risk Data not given.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both patients and investigators were
blinded to the content of identical treat-
ment vials
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Both patients and investigators were
blinded to the content of identical treat-
ment vials
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The report does not state that all 25 ran-
domised participants in each arm com-
pleted the trial, but as the trial finished at
60 mins is it likely that they did
Selective reporting (reporting bias) Unclear risk Trial registered while recruiting. Pre-spec-
ified primary and secondary outcomes are
reported; note omission of PEFR/dyspnoea
scale reporting at 40mins andno data given
to support report of “no treatment-related
complications”. Clear mistakes in report-
ing of vital signs
Hughes 2003
Methods Design: parallel randomised controlled trial.
Method of randomisation: unknown.
Concealment of allocation: yes.
Blinding: double-blinded, placebo-controlled.
Withdrawals/dropouts: 6 (4 COPD, 2 pneumonia).
Participants Location: 2 university hospitals in New Zealand.
Participants: 52 patients, presenting to the emergency department with acute asthma
exacerbation, FEV1 < 50% predicted.
Exclusions: known irreversible lung disease, pneumonia, pregnancy, significant renal/
cardiac impairment, hypotension (sBP < 100 mmHg), required intubation
Interventions Standard of care: salbutamol 2.5 mg nebulised ×1 or more, hydrocortisone 100 mg IV
at presentation.
Treatment: salbutamol 2.5 mg nebule with 2.5 mL isotonic MgSO (250 mmol/L)
every 30 min ×3.
Control: salbutamol 2.5 mg nebule with 2.5 mL normal saline every 30 min ×3.
Participants were unable to distinguish solutions.
Outcomes Measured at baseline and after each treatment (every 30 min ×3): FEV1, % predicted
FEV1, BP, heart rate, O saturation.
Requirement for admission at 90 minutes.
Adverse events: no serious adverse events noted.
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Hughes 2003 (Continued)
Notes Funding: the study was funded by a research grant from the University of Otago. The
study sponsor had no role in study design, data collection, data analysis, data interpre-
tation, or writing of the report
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to
their treatment groups in accordance with
the allocation sequence determined by the
hospital pharmacy
Allocation concealment (selection bias) Unclear risk No information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded, placebo-controlled. Par-
ticipants and investigators were unaware
of treatment allocation through provision
by the hospital pharmacy of pre-prepared
identical unmarked syringes containing the
study drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded, placebo-controlled. Par-
ticipants and investigators were unaware
of treatment allocation through provision
by the hospital pharmacy of pre-prepared
identical unmarked syringes containing the
study drug. Outcomes assessed every 30
minutes
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 in total.
MgSO (1 COPD, 1 pneumonia).
Saline (3 COPD, 1 pneumonia).
Selective reporting (reporting bias) High risk The primary outcome, FEV1, was fully re-
ported but other outcomes were not. “The
change in blood pressure and heart rate
did not differ between the two groups. No
clinically significant adverse events were re-
ported.”
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Methods Parallel RCT.
Participants Location: authors based in Iran.
Participants: 40 asthmatic children in total between 2 groups
Mean age: 3.55 years.
Interventions Intervention: nebulised salbutamol, as a vehicle isotonic MgSO mixed with salbutamol
Control: nebulised salbutamol, as a vehicle 2.5 mL of normal saline
Outcomes Days of hospital stay, hours of need for oxygen, respiratory distress
Measured 1 h before and 1 h after the second course of treatment
Notes Abstract only.
Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly enrolled.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Low risk Outcomes stated as measured, reported. Abstract only.
Kokturk 2005
Methods Parallel RCT
Participants Inclusion criteria: moderate to severe asthma attacks, 18 to 60 years
Exclusion criteria: patients with febrile disease, diabetes, congestive heart failure,
atherosclerotic heart disease, intractable hypertension, chronic obstructive lung disease,
renal and hepatic failure and arrhythmia were excluded from the study. Pregnant and
breast-feedingwomen, patients who had already taken theophylline, antihistaminics, and
systemic steroids in the previous 24 h, who had acute or chronic respiratory failure, who
had been on long-term oxygen therapy, and a history of allergy to salbutamol andMgSO
have been excluded as well
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Location: emergency department, Turkey.
Intervention: 14.
Mean age: 46.43 (years) (3.31) range 18 to 3.
Men:women: 4:10.
Control: 12.
Mean age: 37.83 (years) (9.26) range 20 to 52.
Men:women: 3:9.
Interventions Every 20 mins for first hour and every hour for the rest of 4 h
Intervention: isotonic MgSO (2.5mL) + salbutamol (2.5 mL).
Control: salbutamol (2.5 mL) + saline (2.5 mL).
Outcomes PEF, clinical scores, discharge rates, admission rates.
20th, 60th, 120th , 180th , 240th minute (180 and 240 not compared as most patients
completed study in 2 h)
Notes Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised details of sequence generation not included in
trial report
Allocation concealment (selection bias) Unclear risk Information not available in trial report.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single blind - no further details.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Single blind - no further details.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information provided in trial report on discharges from both
groups up to 240 minutes
Selective reporting (reporting bias) Low risk No apparent indication of selective reporting.
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Mahajan 2004
Methods Design: parallel randomised controlled trial.
Method of randomisation: table of random numbers.
Concealment of allocation: not stated.
Blinding: double-blinded, placebo-controlled.
Withdrawals/dropouts: none described.
Participants Location: 1 paediatric emergency department in Detroit, Michigan.
Participants: 62 patients age 5 to 17, presenting to the emergency department with acute
asthma exacerbation, FEV1 between 45% and 75% predicted.
Exclusions: Fever (> 39 °C), chronic disease (bronchopulmonary dysplasia, cystic fibrosis)
, known allergy to albuterol or magnesium, received any of steroids, theophylline or
ipratropium bromide in the prior 3 days
Interventions Treatment: albuterol 2.5 mg nebule with 2.5 mL isotonic MgSO (6.3% solution); 1
dose.
Control: albuterol 2.5 mg nebule with 2.5 mL normal saline; 1 dose.
Both groups received corticosteroids (2 mg/kg) after inhaled treatment
Outcomes Lung function (FEV1 and % predicted FEV1) at baseline, then at 10 and 20 minutes
after treatment.
Also report vital signs and hospital admission rates.
State that none of the patients showed any side effects.
Notes Funding: this work was funded by an unrestricted grant from the Division of Pediatric
Emergency Medicine, Children’s Hospital of Michigan, Detroit, Michigan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A table of random numbers was used to
provide randomisation and this was per-
formed by a senior research pharmacist at
the institution
Allocation concealment (selection bias) Low risk A table of random numbers was used to
provide randomisation and this was per-
formed by a senior research pharmacist at
the institution
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded, placebo controlled. The
study medications were provided in identi-
cal syringes and both the pharmacy and the
investigator were blinded to their contents
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded, placebo controlled. The
study medications were provided in identi-
cal syringes and both the pharmacy and the
investigator were blinded to their contents.
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Outcomes assessed at 10 and 20 minutes
after treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk None described.
Selective reporting (reporting bias) Low risk All outcomes stated in the methods section
are reported.
Mangat 1998
Methods Design: parallel randomised controlled trial.
Method of randomisation: unknown.
Concealment of allocation: yes.
Blinding: double-blind, placebo-controlled.
Withdrawals/dropouts: 0.
Participants Location: emergency department, St John’s Medical College Hospital, India.
Screened: 63.
Participants: 33, 12 to 60 years of age, known or newly diagnosed asthmatics with PEF
< 300 L/min.
Exclusions: patient enrolled at prior presentation, febrile, lower respiratory tract infec-
tion, history or evidence of cardiac/renal/hepatic dysfunction, pregnancy, requirement
for ventilatory care, oral/parenteral bronchodilators within previous 6 h, steroids within
previous 12 h
Interventions Standard of care: hydrocortisone 100 mg IV.
Treatment: MgSO 3 mL (3.2% solution = 95 mg) nebulised every 20 min ×4.
Control: salbutamol 3 mL (2.5 mg) nebulised every 20 min ×4.
Outcomes Clinical score: Fischl Index, clinical examination.
Pulmonary function: PEF.
Vitals: respiratory rate, heart rate, BP, pulsus paradoxus.
Admission rates, vital signs.
Adverse events/side effects:
• treatment: 1 case mild transient hypotension with spontaneous resolution.
• control group: 1 case mild transient hypotension with spontaneous resolution, 1
case palpitations, 2 cases fine tremors in hand.
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised.
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Allocation concealment (selection bias) Unclear risk Information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled. Out-
comes assessed at 20 minute intervals
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk None described.
Selective reporting (reporting bias) Unclear risk Pulsus paradoxus and BP are mentioned
but not reported, but pulsus paradoxus is
included as part of the Fischl index
Meral 1996
Methods Design: randomised controlled trial.
Method of randomisation: unknown.
Concealment of allocation: unknown.
Blinding: unknown.
Withdrawals/dropouts: 0.
Participants Location: Department of Paediatric Asthma of Ege University Hospital, Turkey.
Participants: 40 randomly selected and divided into 2 groups of 20. Mean ages 10.6 and
11 years of age. Previously diagnosed as asthmatic using ATS definitions; PEF decreased
by ≥ 25%.
Exclusions: medication within 12 h of study, cardiac/renal dysfunction
Interventions Treatment: MgSO 2 mL (280 mmol/L, 258 mOsm, pH 6.7).
Control: salbutamol 2.5 mg in 2.5 mL.
Administration: nebulised, inhaled over 10 to 15 minutes.
Outcomes Evaluations at: 5, 15, 30, 60, 180,240 and 360 minutes.
Clinical score: Davis-Leffert-Dabbous respiratory distress score pulmonary function:
PEF.
Adverse reactions/side effects: none observed.
Notes Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly selected for the
study and divided into 2 groups
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Meral 1996 (Continued)
Allocation concealment (selection bias) Unclear risk Information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk None described.
Selective reporting (reporting bias) High risk No statistical differences were found be-
tween the groups for respiratory rate, heart
rate and BP. It is also unclear as to the time
point reported as although 5 minutes was
prespecified, there were also several other
time points specified and only the maxi-
mum values were presented
Mohammedzadeh 2014
Methods Randomised controlled trial.
1 hospital, Iran.
Participants Inclusion criteria: moderate to severe asthma (GINA-defined) with acute attack
Exclusion criteria: corticosteroid therapy, steroid/theophylline/ipratropium in past 72 h,
chronic lung disease e.g. bronchopulmonary dysplasia/CF, allergy to MgSO or salbu-
tamol, not co-operative
80 randomised.
Intervention 1 (nebulised MgSO ): 40 randomised.
Mean age (years): 9 (2.2).
Male:female: 10:30.
Control: 40 randomised.
Mean age (years): 8.5 (2.4)
Male:female: 17:23.
Interventions Intervention: 3 mL 7.5% MgSO , 0.15 mg/kg salbutamol.
Control: 3 mL normal saline, 0.15 mg/kg salbutamol.
3 doses at 20 minute intervals.
Outcomes Pulmonary index, PEFR, adjusted PEFR at 30, 60 and 90 minutes
Notes Funding: Babol University of Medical Sciences Research and Technology Institute
Risk of bias
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Mohammedzadeh 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “divided into two groups ran-
domly” but no details given
Allocation concealment (selection bias) Unclear risk Data not given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as “double-blind” in prospective
trial registration but no details given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as “double-blind” in prospective
trial registration but no details given
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants lost to follow-up.
Selective reporting (reporting bias) Low risk Prospectively registered; planned outcomes
were fully reported
Nannini 2000
Methods Design: randomised controlled trial.
Method of randomisation: unknown.
Concealment of allocation: yes.
Blinding: double-blind, placebo-controlled.
Solutions were pre-packaged in identical appearing vials.
Withdrawals/dropouts: 3 participants were enrolledmore than once, only the initial visit
was used in the analysis
Participants Location: emergency departments in 4 Argentinian hospitals.
Participants: 35 patients at least 18 years of age presenting to the emergency department
with an acute asthma exacerbation who were able to have PEF measured were enrolled.
(% predicted PEF: 38 + 18 in treatment group, 38 + 12 in control group).
Exclusions: current smokers of ≥ 5 pack years, concurrent medical illness, pregnant,
breast feeding, oral or parenteral steroids within the previous 7 days
Interventions Standard of care: all patients received supplemental oxygen. If patient conditionworsened
patient may receive salbutamol 2.5 mg nebulised at discretion of physician.
Treatment: 0.5 mL salbutamol (2.5 mg) diluted in 3 mL isotonic MgSO (286 mOsm,
7.5% = 225 mg).
Control: 0.5 mL salbutamol (2.5 mg) diluted in 3 mL normal saline.
Administration: jet nebulised using oxygen at 10 L/min via mouthpiece until dry
Outcomes Measurements made at baseline, 10 minutes after treatment and 20 minutes after treat-
ment.
Pulmonary functions: primary endpoint : % increase in peak flow = ((change/baseline)
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Nannini 2000 (Continued)
× 100).
Other: peak flow (best of 3 attempts).
Vital signs: respiratory rate, pulse rate, BP.
Duration of emergency room care.
No adverse events reported in either the experimental or control group
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised.
Allocation concealment (selection bias) Unclear risk Information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled.
Incomplete outcome data (attrition bias)
All outcomes
High risk 3 patients were enrolled more than once,
only the initial visit was used in the analysis
but treatment group not stated
Selective reporting (reporting bias) High risk There were no significant differences be-
tween the groups in changes in BP, heart
rate, or respiratory rate at either 10minutes
or 20 minutes
Neki 2006
Methods Parallel.
Participants Inclusion criteria: patients in age group of 15 to 60 years with severe bronchial asthma,
as judged by Fischl index having PEF < 300 L/min or FEV in 1st second less than 40%
of the predicted value were included in the study
Exclusion criteria: all patients who had received oral inhaler or parenteral bronchodilators
in the past 6 h or steroid in the previous 12 h were excluded from the study
Adults and children with severe asthma (15 to 60 years) 40 participants
30 female and 10 male but unclear how divided between groups
Intervention: 20 completed.
Control: 20 completed.
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Neki 2006 (Continued)
Interventions Intervention: given 4 doses of nebulised solution of “3.2G%”MgSO , 20 minutes apart
Control: received 4 doses of nebulised salbutamol (each dose of 3 mL containing 25 mg)
, 20 minutes apart
Outcomes PEF (L/min),
respiratory rate, Fischl index and SaO .
Notes Abstract only.
Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details of random sequence generation not included in trial
report. There is no reference to randomisation in trial report
and trial not reported as randomised - seeking clarification from
author
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not included in trial report.
There is no reference to randomisation in trial report and trial
not reported as randomised - seeking clarification from author
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details of blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk If the trial was not blinded, there is a strong likelihood that
outcome assessment was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information.
Selective reporting (reporting bias) Unclear risk Abstract only. No apparent indication of selective reporting
Powell 2013
Methods Double blind, randomised controlled trial.
30 emergency departments or children’s assessment units, UK.
Participants Inclusion criteria: severe (BTS/SIGN quantified) asthma exacerbation after conventional
treatment, age 2 to 16 years
Exclusion criteria: coexisting respiratory disease, severe renal disease, severe liver disease,
known pregnancy, known previous reaction to magnesium, inability to give informed
consent, previous randomisation into the trial, life-threatening symptoms, current or
previous (in the 3 months preceding screening) involvement with a trial of a medicinal
product
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Powell 2013 (Continued)
508 randomised.
Intervention: 252 randomised.
Median age (years): 4 (3 to 7).
Male:female: 143:109.
Control: 256 randomised.
Median age (years): 4 (3 to 7).
Male:female: 150:106.
Interventions Intervention: 2.5 mL MgSO (250 mmol/L) nebulised.
Control: 2.5 mL isotonic saline nebulised.
3 doses given at roughly 20 minute intervals.
Outcomes Mean Yung asthma severity score, treatment step-down (60 minutes); length of stay,
need for additional intravenous bronchodilator, admission to PICU/HDUor intubation,
adverse events (until discharge)
Adverse events: treatment group 47, control group 59
Notes Funding: National Institute of Health Research Health Technology Assessment Pro-
gramme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated blocked randomisa-
tion sequence stratified by centre was gen-
erated by an independent statistician who
had no further involvement in the study
Allocation concealment (selection bias) Low risk Treatment packs were identical in appear-
ance and numbered sequentially for each
centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants (patients, clinicians, re-
search team, and statisticians) were masked
to the treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The statistical analyses were completed
with masked data, with treatment groups
revealed only after final analyses had been
completed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Over 90% randomised participants in each
arm were included in the adjusted primary
analysis. All participants who withdrew or
were excluded are clearly accounted for in
the flow diagram
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Powell 2013 (Continued)
Selective reporting (reporting bias) Low risk Prospectively registered trial. All listed out-
comes are reported
Sarhan 2016
Methods Double blind, randomised controlled trial.
Chest and emergency departments at 1 hospital, Egypt.
Participants Inclusion criteria: diagnosis of asthma.
Exclusion criteria: fever, lower respiratory tract infection, cardiac/renal/hepatic dysfunc-
tion, needed NIV/intubation, near-fatal asthma, pregnancy, lactation, failed to use PEF
meter, inhaled/oral/intravenous bronchodilator use within past 6 h or steroid use within
past 12 h
30 randomised.
Intervention 1 (magnesium): 10 randomised.
Mean age (years): 33.5 (17.8).
Men:women: 4:6.
Mean % of predicted PEF at presentation: 33.9 (9.8).
Intervention 2 (salbutamol and placebo) : 10 randomised.
Mean age (years): 48.6 (9.9).
Men:women: 3:7.
Mean % of predicted PEF at presentation: 36.4 (10.5).
Intervention 3 (salbutamol and magnesium): 10 randomised.
Mean age (years): 51.3 (15.8).
Men:women: 7:3.
Mean % of predicted PEF at presentation: 34.1 (9.4).
Interventions Intervention 1: 3 mL MgSO (3.3% solution) nebulised.
Intervention 2: 0.5 mL salbutamol (0.5% solution) in 2.5 mL isotonic saline nebulised
Intervention 3: 0.5 mL salbutamol (0.5% solution) in 2.5 mL MgSO (4% solution)
nebulised
4 doses given at 20 minute intervals.
Ultrasonic nebuliser.
Outcomes PEF improvement, respiratory rate, heart rate, blood pressure, oxygen saturations, im-
provement in Fischl index of clinical severity, adverse event rate (all at “final” time point,
assumed to be 2 h)
Adverse events: no events “severe enough to warrant withdrawal” reported
Notes Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reports patients were randomised into 3
groups but no details given
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Sarhan 2016 (Continued)
Allocation concealment (selection bias) Unclear risk Data not given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as “double blind” but no details
given about who was blinded or how
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as “double blind” but no details
given about who was blinded or how
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The report does not specify how many ran-
domised participants completed the trial
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified.
Primary and secondary outcomes not de-
fined. No power calculation reported
Turker 2017
Methods Double blind, randomised controlled trial.
1 emergency department, Turkey
Participants Inclusion criteria: children aged 3 to 15 years with asthma admitted to the emergency
department due to a moderate asthma exacerbation
Exclusion criteria: any associated chronic diseases such as cystic fibrosi and bronchiectasis
100 randomised.
Intervention: 50 randomised.
Mean age, months (SD): 76.06 (27.33).
Male:female: 25:25.
Median (IQR) modified pulmonary index score at presentation 8 (7-8)
Control: 50 randomised.
Mean age, months (SD): 74.96 (33.65).
Male:female: 29/21.
Median (IQR) modified pulmonary index score at presentation 7 (7 to 9)
Interventions Intervention: nebulised salbutamol (0.15 mg/kg) + 1 mL magnesium sulfate (15%) + 1.
5 mL isotonic saline
Control: nebulised salbutamol (0.15 mg/kg) + 1.5 mL isotonic saline
3 doses given at 20 min intervals.
Outcomes Primary outcome: Modified Pulmonary Index Score (MPIS); secondary outcomes: hos-
pitalisation rates, symptoms of magnesium imbalance such as nausea, vomiting, abdom-
inal pain, chest pain, headache, fatigue, hypotension and fever
Notes Funding: “this research did not receive any specific grant from funding agencies in the
public, commercial, or not-for-profit sectors”
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Turker 2017 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were assigned consecutively to the
control or intervention group based on a
stratified randomisation procedure” but no
further detail about how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Data not given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as “double-blind” but no details
of who was blinded and the blinding pro-
cedure
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as “double-blind” but no details
of who was blinded and the blinding pro-
cedure
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All patients enrolled in the study com-
pleted it”.
Selective reporting (reporting bias) High risk No trial registration or prospective protocol
identified. Adverse events reported as: “no
side effect caused by magnesium was ob-
served in any of the patients in the study”.
Modified pulmonary index score reported
numerically at 120 minutes only; other
time points presented graphically with no
measure of variance
ASS: Asthma Severity Score (ASS)
ATS: American Thoracic Society
BP: blood pressure
BTS: British Thoracic Society
COPD: Chronic obstructive pulmonary disease
ED: emergency department
FEV1: Forced expiratory volume in 1 second
FVC: Forced vital capacity
h: hour(s)
IV: intravenous
MDI: metered dose inhaler
MgSO : magnesium sulfate
PEF: Peak Expiratory Flow Rate
R&D: research and development
sBP: systolic blood pressure
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SD: standard deviation
SIGN: Scottish Intercollegiate Guidelines Network
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Balter 1989 Review
Bede 2003 Oral supplementation in chronic asthma
Bede 2004 Oral supplementation in chronic asthma
Bede 2008 Oral supplementation in chronic asthma
Bernstein 1995 Study does not assess people with acute asthma
Cairns 1996 Study does not assess people with acute asthma
Castillo Rueda 1991 Letter to the Editor
Chande 1992 Study of stable asthma and methacholine challenge tests
Corbridge 1995 Review
DiGregorio 1999 Not a randomised controlled study
Emelyanov 1997 Study not a randomised trial and in mild-to-moderate persistent asthma rather than acute asthma
Emelyanov 1990 Not a randomised controlled trial
Emelyanov 1996 Exercise induced bronchospasm and challenge test. Not a randomised controlled trial
Fathi 2014 Oral supplementation in chronic asthma
Fedoseev 1991 Study does not assess people with acute asthma and is not a randomised controlled trial
Gandia 2012 Study of stable asthma and methacholine challenge tests
Gurkan 1999 Randomised controlled trial of intravenous MgSO4
Harari 1998 Review
Hardin 2001 Review
Harmanci 1996 Stable asthma histamine-induced bronchospasm adults
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(Continued)
Hill 1995 Study does not assess people with acute asthma. Dose response study in 20 normal individuals and 19 with
chronic asthma
Hill 1997a Study does not assess people with acute asthma. Stable asthma histamine challenge tests
Hill 1997b Stable adult asthma with histamine challenges
Irazuzta 2014 Randomised controlled trial of intravenous MgSO
Irazuzta 2016 Randomised controlled trial of intravenous MgSO
Kenyon 2001 Review
Kreutzer 2001 Review
Manzke 1990 Paediatric exercise-induced bronchospasm. Not a randomised controlled trial
McFadden 1995 Review
Nannini 1997 Study does not assess people with acute asthma
Nunez-Torres 1995 Not a randomised controlled trial
Pelton 1998 Study does not assess people with acute asthma
Pelton 1999 Review
Petrov 2014 Oral supplementation in uncontrolled and partly controlled atopic asthma
Puente-Maestu 1999 Review
Qureshi 1999 Review
Rodger 2003 Oral supplementation on people with unstable asthma
Rodrigo 2000 Systematic review, includes intravenous MgSO
Rolla 1987a Study does not assess people with acute asthma
Rolla 1987b Study does not assess people with acute asthma
Rolla 1988a Study does not assess people with acute asthma
Rolla 1988b Letter to the editor
Scarfone 1998 Randomised controlled trial of intravenous MgSO
68Inhaled magnesium sulfate in the treatment of acute asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Scarfone 2000 Intravenous MgSO
Shishimorov 2015 Oral supplementation in children with uncontrolled asthma
Singh 2008a Intravenous MgSO
Singh 2008b Comparison between inhaled versus intravenous MgSO
Singhi 2014 Randomised controlled trial of intravenous MgSO
Sinitsina 1991 Not a randomised controlled trial
Skobeloff 1982 Editorial
Sun 2014 Study of stable asthma and methacholine challenge tests
Talukdar 2005 Not a randomised controlled trial
Teeter 1999 Review
Telia 2005 Study does not assess people with acute asthma
Tereshchenko 2006 Looking at ipratropium bromidemixed with eitherMgSO or saline for bronchiolitis (up to age 11.5months)
Tetikkurt 1992 Study does not assess people with acute asthma
Tetikkurt 1993 Study does not assess people with acute asthma
Torres 2012 Randomised controlled trial of intravenous MgSO
Watanatham 2015 Randomised controlled trial of intravenous versus nebulised MgSO
Wijetunge 2002 No response to attempts made to contact first author from 2002 to 2012. First author sadly died in 2014
Wongwaree 2017 Randomised controlled trial of nebulizedmagnesium sulfate versus ipratropiumbromide/fenoterol in children
with severe asthma exacerbation
Xu 2002 Not a randomised controlled trial
Yemelyanov 1997 Study does not assess people with acute asthma
Zandsteeg 2009 Study does not assess people with acute asthma (stable chronic asthma) and is not a randomised controlled
trial
Zhu 2003 Intravenous MgSO and not a randomised controlled trial
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MgSO : magnesium sulfate
Characteristics of studies awaiting assessment [ordered by study ID]
Abd 1997
Methods “Ventilatory, cardiovascular and metabolic responses to salbutamol, ipratropium bromide and magnesium sulfate in
bronchial asthma: comparative study”
Participants No details
Interventions No details
Outcomes No details
Notes Full-text unobtainable
Bustamante 2000
Methods “Inhaled magnesium sulfate as adjunct therapy for moderate to severe asthma exacerbations, a randomized control
clinical trial”
Participants No details
Interventions No details
Outcomes No details
Notes Full-text unobtainable
ISRCTN61336225
Methods Prospective double-blind placebo controlled trial
Participants Children diagnosed as asthmatic according to The Global Initiative for Asthma (GINA) guidelines, aged 5 to 14
years old, capable of measuring PEFR, presenting with moderate to severe acute exacerbation according to paediatric
asthma severity score and PEFR
Interventions Group A: participants receive inhaled salbutamol solution (0.15 mL/kg) plus isotonic magnesium sulfate (2 mL) in
a nebulizer chamber;
Group B: participants receive inhaled salbutamol solution (0.15 mL/kg), diluted with placebo (normal saline 2 mL)
in a nebulizer chamber
Outcomes 1. Asthma severity measured using the Pediatric Asthma Severity Score (PASS) at baseline, 20, 40 and 60 minutes
post-nebulisation
2. Oxygen saturation measured using pulse oximetry at baseline, 20, 40 and 60 minutes post-nebulisation
3. Lung function assessed through measuring peak expiratory flow rate (PEFR) at baseline, 20, 40 and 60 minutes
post-nebulisation
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ISRCTN61336225 (Continued)
Notes Trial stated as complete February 2016 but no associated publication identified. Contact person emailed on 7
September 2017 to enquire about status of results/publication. No response received at time of review publication
Characteristics of ongoing studies [ordered by study ID]
Motamed 2015
Trial name or title Comparison of clinical and spirometric response between nebulized salbutamol, MgSO and nebulized
salbutamol alone in acute asthma attack
Methods Randomized, double-blind controlled trial
1 hospital, Iran
Participants Inclusion criteria: having a history of asthma, a minimum 18 years and maximum 65 years
Exclusion criteria: COPD; kidney disease; CHF; pneumonitis; underlying respiratory disease
146 randomised
Interventions Intervention: nebulized MgSO 1/5 mL (20 g / 100 mL) with salbutamol 2/5 mL
Control: normal saline with nebulized salbutamol 2/5 mL
Outcomes Clinical state, FEV1, PEFR
Starting date 22 March 2014
Contact information Hasan motamed@yahoo.com
Notes
Saucedo 2015
Trial name or title Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation
Methods Randomized, double-blind controlled trial
1 paediatric emergency department, Mexico
Participants Inclusion criteria: clinical history of asthma, clinical diagnosis of moderate or severe asthma exacerbations,
age 2 to 15 years
Exclusion criteria: coexistence of lung disease, severe kidney or liver disease, pregnancy, previous reaction to
magnesium, no parental consent, prior inclusion in this study, presence of life-threatening co-morbidities,
need for advanced airway management, life-threatening symptoms
Estimated enrolment: 152
Interventions Intervention: nebulized salbutamol 2.5 mg (2 to 5 years) or 5 mg (≥ 6 years) and ipratropium bromide
250 mcg mixed with 2.5 mL of isotonic MgSO (150 mg) per dose every 20 minutes during the first
hour, continued with nebulized standard treatment every hour for 4 h, plus IV methylprednisolone or PO
prednisolone 2 mg/kg/day for each treatment
Control: nebulized salbutamol 2.5 mg (2-5 years) or 5 mg (≥ 6 years) and ipratropium bromide 250 mcg
71Inhaled magnesium sulfate in the treatment of acute asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Saucedo 2015 (Continued)
mixed with 2.5mL of isotonic saline per dose every 20minutes during the first hour, continued with nebulized
standard treatment every hour for 4 h, plus IV methylprednisolone or PO prednisolone 2 mg/kg/day for each
treatment
Outcomes Primary outcome measure: change from Baseline Preschool Respiratory Assessment Measure (PRAM) at 20,
40, 60, 120, 180 and 240 minutes after beginning treatment
Secondary outcome measures: rate of hospitalisation at 4 h, change from baseline heart rate, respiratory rate
and blood pressure at 20, 40, 60, 120, 180 and 240 minutes after beginning treatment
Starting date September 2015
Contact information abisaipec@msn.com
Notes Estimated study completion date: January 2018
Schuh 2016a
Trial name or title Magnesium nebulization utilization inmanagement of paediatric asthma (MagNUMPA) trial: study protocol
for a randomized controlled trial
Methods Randomized double-blind controlled trial in 7 Canadian paediatric emergency departments
Participants The trial will include 816 otherwise healthy children who are 2 to 17 years old, having had at least 1 previous
wheezing episode, have received systemic corticosteroids, and have a Pediatric Respiratory AssessmentMeasure
(PRAM) ≥ 5 points after 3 salbutamol and ipratropium treatments for a current acute asthma exacerbation
Interventions 3 doses nebulized salbutamol with either 600 mg MgSO or placebo 20 min apart
Outcomes Primary outcome: hospitalisation within 24 h of the start of the experimental therapy for persistent respiratory
distress or supplemental oxygen
Secondary outcomes include all-cause hospitalisation within 24 h, PRAM, vital signs, number of bronchodila-
tor treatments by 240 min, association between the difference in the primary outcome between the groups,
age, gender, baseline PRAM, atopy, and “viral induced wheeze” phenotype
Starting date November 2014
Contact information Suzanne Schuh: Suzanne.schuh@sickkids.ca
Division of Paediatric EmergencyMedicine, TheHospital for SickChildren,ChildHealth Evaluative Sciences,
SickKids Research Institute, University of Toronto, 555 University Avenue, Toronto, ONM5G 1X8, Canada
Notes Estimated completed: December 2017
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. MgSO4 + SABA + ipratropium versus SABA + ipratropium
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pulmonary function (% FEV1) 2 120 Mean Difference (IV, Fixed, 95% CI) 3.28 [1.06, 5.49]
1.1 90 minutes 1 60 Mean Difference (IV, Fixed, 95% CI) 8.57 [1.99, 15.15]
1.2 120 minutes 1 60 Mean Difference (IV, Fixed, 95% CI) 2.60 [0.25, 4.95]
2 Pulmonary function % predicted
PEF
2 636 Mean Difference (IV, Fixed, 95% CI) 0.05 [-2.33, 2.42]
3 Clinical severity scores (closest
to 60 mins)
2 1130 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.11, 0.12]
3.1 Yung ASS at 60 minutes 1 472 Std. Mean Difference (IV, Fixed, 95% CI) -0.17 [-0.35, 0.02]
3.2 Change in dyspnoea VAS
at 60 minutes
1 658 Std. Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.02, 0.28]
4 Admission at first presentation 4 1308 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.91, 1.00]
4.1 Adults 3 800 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.87, 1.03]
4.2 Children 1 508 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.92, 1.01]
5 HDU/ITU admission 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Admission to HDU
(adults)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Admission to ICU (adults) 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Admission to PICU/
HDU or intubation (children)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Readmission 2 750 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.84, 3.87]
7 Respiratory rate at 60 mins 2 723 Mean Difference (IV, Fixed, 95% CI) 0.70 [-0.14, 1.53]
8 Heart rate at 60 mins 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9 Systolic blood pressure at 60
mins
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10 Diastolic blood pressure at 60
mins
1 674 Mean Difference (IV, Fixed, 95% CI) 2.40 [0.29, 4.51]
11 Serious adverse events (during
admission)
2 557 Risk Difference (M-H, Fixed, 95% CI) -0.03 [-0.06, -0.00]
11.1 Adults 1 50 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.07, 0.07]
11.2 Children 1 507 Risk Difference (M-H, Fixed, 95% CI) -0.04 [-0.06, -0.01]
12 Any adverse event (during
admission)
2 1197 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.03, 0.05]
12.1 Adults 1 690 Risk Difference (M-H, Fixed, 95% CI) 0.02 [-0.02, 0.07]
12.2 Children 1 507 Risk Difference (M-H, Fixed, 95% CI) -0.02 [-0.09, 0.05]
13 Serious adverse events (within
30 days)
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
14 Any adverse event (within 30
days)
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
15 Adverse event: hypotension 2 1197 Risk Difference (M-H, Fixed, 95% CI) 0.02 [-0.01, 0.04]
15.1 Adults 1 690 Risk Difference (M-H, Fixed, 95% CI) 0.03 [-0.01, 0.07]
15.2 Children 1 507 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.02, 0.01]
16 Adverse event: flushing 2 1197 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.01, 0.01]
16.1 Adults 1 690 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.01, 0.02]
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16.2 Children 1 507 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.02, 0.01]
Comparison 2. MgSO4 + SABA versus SABA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pulmonary function % predicted
FEV1
4 208 Mean Difference (IV, Fixed, 95% CI) 3.34 [-1.58, 8.26]
1.1 Adults 3 146 Mean Difference (IV, Fixed, 95% CI) 2.18 [-3.30, 7.67]
1.2 Children 1 62 Mean Difference (IV, Fixed, 95% CI) 8.10 [-3.03, 19.23]
2 % predicted FEV1: subgroup:
severity
3 188 Mean Difference (IV, Fixed, 95% CI) 4.12 [-1.81, 10.06]
2.1 Severe (FEV1 <50%
predicted)
1 52 Mean Difference (IV, Fixed, 95% CI) 9.90 [0.05, 19.75]
2.2 Moderate 2 136 Mean Difference (IV, Fixed, 95% CI) 0.84 [-6.59, 8.27]
3 Pulmonary function PEF L/min 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Adults 3 155 Mean Difference (IV, Fixed, 95% CI) 11.91 [-4.12, 27.95]
3.2 Children 1 80 Mean Difference (IV, Fixed, 95% CI) 11.90 [-6.86, 30.66]
4 Admission to hospital 6 375 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.52, 1.15]
4.1 Adults 4 213 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.45, 1.07]
4.2 Children 2 162 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.44, 2.98]
5 Heart rate at 120 mins 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Respiratory rate at 120 mins 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7 Diastolic blood pressure at 120
mins
2 120 Mean Difference (IV, Fixed, 95% CI) 0.72 [-1.35, 2.80]
8 Systolic blood pressure at 120
mins
2 120 Mean Difference (IV, Fixed, 95% CI) 0.89 [-2.69, 4.48]
9 Serious adverse events 5 243 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.04, 0.04]
9.1 Adults 4 181 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.04, 0.04]
9.2 Children 1 62 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.06, 0.06]
10 Any adverse events 5 694 Risk Difference (M-H, Fixed, 95% CI) -0.01 [-0.05, 0.03]
10.1 Adults 4 329 Risk Difference (M-H, Fixed, 95% CI) -0.02 [-0.10, 0.06]
10.2 Children 1 365 Risk Difference (M-H, Fixed, 95% CI) -0.01 [-0.03, 0.01]
Comparison 3. MgSO4 versus SABA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical severity score 3 93 Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.62, 0.36]
1.1 Fischl index final score
(120 mins)
1 33 Mean Difference (IV, Fixed, 95% CI) -0.33 [-1.07, 0.41]
1.2 Fischl index score (time
point unclear)
1 40 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.11, 0.71]
1.3 Change in Fischl index at
120 mins
1 20 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.67, 1.27]
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2 Admission to hospital 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Heart rate (120 mins) 1 20 Mean Difference (IV, Fixed, 95% CI) 21.20 [0.17, 42.23]
4 Respiratory rate 2 60 Mean Difference (IV, Fixed, 95% CI) -2.40 [-3.91, -0.89]
5 Systolic pressure (120 mins) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6 Diastolic pressure (120 mins) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7 Serious adverse events 2 53 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.10, 0.10]
8 Mild-Moderate Side Effects 1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
A D D I T I O N A L T A B L E S
Table 1. Summary of Severity
Study Severity of asthma exacerbation Diagnosis based on Population (adult/mixed/pae-
diatric)
MgSO and SABA and Ipratropium bromide versus SABA and Ipratropium
Ashtekar 2008 Severe BTS definition clinical features Paediatric (2 to 16)
Drobina 2006 Unclear PEF and clinical signs Adults
Gallegos-Solórzano 2010 Moderate to severe FEV1 < 60% Adults >18
Gaur 2008 Severe FEV1 < 30% Adults (18 to 60)
Goodacre 2013 Severe BTS definition Adult (≥ 16)
Hossein 2016 Moderate to severe PEF < 70% and clinical signs Adult (> 16)
Powell 2013 Severe after conventional treat-
ment
BTS definition Paediatric (2 to 16)
MgSO4 and SABA versus SABA
Abreu-Gonzalez 2002 Moderate FEV1 and PEF at baseline Adults
Aggarwal 2006 Severe and life threatening BTS definition clinical features
and PEF
Mixed (13 to 60)
Ahmed 2013 Severe PEF Not documented
Alansari 2015 Moderate to severe Clinical score Paediatric (2 to 14)
Badawy 2014 Unclear N/A Adult
Bessmertny 2002 Moderate to severe PEF between 40% to 80% Adults (18 to 65)
Dadhich 2005 Severe PEF < 50% Adults
Hughes 2003 Severe FEV1 < 50% Adults (16 to 65)
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Table 1. Summary of Severity (Continued)
Khashabi 2008 Unclear Clinically defined as respiratory
distress
Paediatric (mean age 3.55 years)
Kokturk 2005 Moderate to severe Clinical scores and PEF Adults (18 to 60)
Mahajan 2004 Moderate to severe FEV1 between 45% and 75% Paediatric (5 to 17)
Mohammedzadeh 2014 Moderate to severe GINA definition Paediatric (5 to 14)
Nannini 2000 Severe PEF < 50% Adult (> 18)
Sarhan 2016 Unclear PEF < 300L/min Mixed (11 to 70)
Turker 2017 Moderate Not described Children (3 to 15)
MgSO versus SABA
Dadhich 2005 Severe PEF < 50% Adults
Mangat 1998 Moderate to severe PEF < 300 L/Min Mixed (12 to 60)
Meral 1996 Moderate to severe PEF < 75% Paediatric
Neki 2006 Severe FEV1 < 40% or PEF < 300 L/
Min
Adult (15 to 60)
Sarhan 2016 Unclear PEF < 300L/min Mixed (11 to 70)
BTS: British Thoracic Society
GINA: Global Initiative for Asthma
FEV1: Forced expiratory volume in one second
PEF: Peak Expiratory Flow Rate
Table 2. Summary of Characteristics of the studies - where patients were recruited from, additional treatment, exclusion
criteria and side effects.
Study Presenta-
tion to which
department?
Origin Primary out-
come(s)
Total n ran-
domised
Side effects
(patients in
study)
Pharmaceuti-
cal exclusions
Other Inter-
ventions
MgSO and SABA and Ipratropium bromide versus SABA and Ipratropium
Ashtekar 2008 Children’s As-
sessment Unit
after GP refer-
ral
Cardiff, Wales ASS (Yung) 17 1 tingling in
fingers and 1
transient hy-
potension
None stated All manage-
ment followed
the BTS/
SIGN guide-
76Inhaled magnesium sulfate in the treatment of acute asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Summary of Characteristics of the studies - where patients were recruited from, additional treatment, exclusion
criteria and side effects. (Continued)
lines; all chil-
dren received
2 mg/kg pred-
nisolone
Drobina 2006 ED USA PEF,
admissions
110 No comment
on side effects
in paper
Not stated All subjects re-
ceived 50 mg
of oral pred-
nisone at the
onset of the
treatment
Gallegos-
Solórzano
2010
ED Mexico City,
Mexico
% change
FEV1,
O post treat-
ment, admis-
sion rates
112 Dry and bitter
mouth
(MgSO
group 1),
dizzi-
ness (MgSO
1; placebo 1)
Use of steroids
prior to pre-
sentation
All partici-
pants received
one IV dose of
125 mg
methylpred-
nisolone at ad-
mission and 1
mg/kg/day for
10 days pred-
nisolone,on
dis-
charge. Other
treatments
were ad-
ministered ac-
cording to the
treating physi-
cian
Gaur 2008 ED Delhi, India FEV1 60 None
reported
None stated All partici-
pants received
IV hydrocorti-
sone on arrival
Goodacre
2013
ED UK Admission
within 7d, vi-
sual
analogue scale
for breathless-
ness at 2 h
703 AEs
(41 MgSO /
salbutamol;
36 placebo/
salbutamol)
MgSO in the
past 24 h
All
participants
were managed
accord-
ing to BTS/
SIGN guide-
lines (consist-
ing of
oxygen, nebu-
lised salbuta-
mol
(5 mg), nebu-
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Table 2. Summary of Characteristics of the studies - where patients were recruited from, additional treatment, exclusion
criteria and side effects. (Continued)
lised ipra-
tropium (500
µg), and oral
prednisolone
admin-
istered during
recruitment,
followedby up
to 5 mg salbu-
tamol
added to each
trial nebuliser.
Other
treatments
were provided
at the dis-
cretion of the
clinician
Hossein 2016 ED Tehran, Iran PEFR
improvement,
admission rate
50 No
serious side ef-
fects reported
None stated All partici-
pants received
50 mg oral
prednisolone
Powell 2013 ED and chil-
dren’s assess-
ment units
UK Yung asthma
severity score
508 47 in MgSO
group and
59 in control
group
None Hospital-de-
fined conven-
tional
treatment
MgSO4 and SABA versus SABA
Abreu-
Gonzalez
2002
- Tenerife Spain FEV1, PEF 24 None
reported
None stated Not stated
Aggarwal
2006
ED NewDelhi In-
dia
PEF 100 Palpita-
tions (MgSO
/salbuta-
mol 13; salbu-
tamol/placebo
11) and
tremors (7; 7)
None stated Clinicians free
to administer
steroids,
salbutamol,
IV hydrocorti-
sone if judged
to be required
Ahmed 2013 - Mymensingh,
Bangladesh
PEF 120 None
reported
None stated Not stated
Alansari 2015 Pae-
diatric emer-
gency centre
Doha, Qatar Time to readi-
ness for dis-
charge
400 Chest tight-
ness and facial
rash (MgSO
None stated All partici-
pants received
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Table 2. Summary of Characteristics of the studies - where patients were recruited from, additional treatment, exclusion
criteria and side effects. (Continued)
/salbuta-
mol 191), ex-
cessive cough
(placebo/
salbutamol
174)
methylpred-
nisolone 1
mg/kg IV ev-
ery 12h
and additional
nebulised al-
buterol at clin-
icians’ discre-
tion
Badawy 2014 Outpatient
department
and ED
Sohag, Egypt Exacerbations
post interven-
tion, delivery
outcome,
post-partum
health status
60 None
reported
None stated All partici-
pants received
100
mg hydrocor-
tisone IV, 500
mg amino-
phylline IV
Bessmertny
2002
ED Brooklyn,
USA
FEV1 (%
pred)
74 No SAEs re-
ported
No theo-
phylline or an-
ti-
cholinergics 2
h prior to pre-
sentation
Intravenous
hydrocorti-
sone, 2 mg/kg
every 6 h, was
ad-
ministered to
patients who
failed to show
an adequate
improvement
of pulmonary
function after
3 initial doses
of albuterol
Dadhich 2005 ED Ajmer India PEF 71 “Side effects
were self limit-
ing”
Not stated Not stated
Hughes 2003 ED Wellington
New Zealand
FEV1 52 None
reported
None All partici-
pants received
100
mg hydrocor-
tisone IV
Khashabi
2008
- Urmia, Iran Reduced
mean
duration of O
ther-
apy in MgSO
group,
40 No side effects Not stated Not stated
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Table 2. Summary of Characteristics of the studies - where patients were recruited from, additional treatment, exclusion
criteria and side effects. (Continued)
no change in
Respi-
ratory Distress
Score)
Kokturk 2005 ED Gazi, Turkey PEF
difference
26 Tran-
sient hypoten-
sion (1 MgSO
), palpitation
(1 salbutamol)
None All partici-
pants received
1 mg/kg pred-
nisolone.
Theophylline,
anticholiner-
gics and salbu-
tamol given at
clinicians dis-
cretion
Mahajan 2004 ED Detroit, USA % change in
FEV1
62 No side effects Steroids, ipra-
tropium or
theo-
phylline in the
last 3 days.
All partici-
pants received
2 mg/kg of
prednisone
Mo-
hammedzadeh
2014
- Babol, Iran Pulmonary in-
dex, PEFR,
adjusted
PEFR
80 - Corticos-
teroids;
steroids, theo-
phylline or
ipratropium
use within last
72 h
Not stated
Nannini 2000 ED 4 hospitals in
Argentina
PEF,
admissions
35 None
reported
Oral or par-
enteral
steroids in the
last 7 days
No
other medica-
tions were per-
mitted during
the study ex-
cept
supplemental
oxygen; if the
patient’s con-
dition wors-
ened, a 2.5 mg
dose of neb-
ulized salbuta-
mol was ad-
ministered at
the discretion
of the treating
physician
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Table 2. Summary of Characteristics of the studies - where patients were recruited from, additional treatment, exclusion
criteria and side effects. (Continued)
Sarhan 2016 Chest and ED Minia, Egypt Clin-
ical improve-
ment, PEFR
30 None se-
vere enough to
warrant with-
drawal
Bronchodila-
tors in last 6 h,
steroids in last
12 h
Neb-
ulised salbuta-
mol, IV hy-
drocortisone,
IV amino-
phylline at
clinicians’ dis-
cretion
Turker 2017 ED Turkey Modified pul-
monary index
score
100 “No side ef-
fect caused by
magne-
sium was ob-
served in any
of the patients
in the study”
Not stated Neb-
ulised salbuta-
mol (0.15 mg/
kg), methyl-
prednisolone
1 mg/
kg IV; Oxygen
was given to
patients with
SaO2≤ 95%
MgSO versus SABA
Dadhich 2005 ED Ajmer India PEF 71 “Side effects
were self limit-
ing”
Not stated Not stated
Mangat 1998 ED St John’s Col-
lege, India
PEF, Fischl in-
dex score, ad-
missions
33 Transient self
limiting hy-
potension (1)
palpitation (1)
tremors (2) all
in con-
trol group and
only 1 tran-
sient hypoten-
sion in MgSO
group (33)
Oral par-
enteral bron-
chodilators (6
h) steroids
(last 12 h)
All partici-
pants received
100
mg hydrocor-
tisone IV
Meral 1996 - Izmir, Turkey % change in
PEF
ASS (Davies
Leffert, Dab-
bous score)
40 No side effects Beta2-ag-
onists or theo-
phylline in the
last 12 h
No
other medica-
tion given
Neki 2006 - Amritsar Pun-
jab
PEF, RR, Fis-
chl index
40 - Oral, inhaled
or parenteral
steroids in last
12 h
All partici-
pants received
100
mg hydrocor-
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Table 2. Summary of Characteristics of the studies - where patients were recruited from, additional treatment, exclusion
criteria and side effects. (Continued)
tisone IV
Sarhan 2016 Chest and ED Minia, Egypt Clin-
ical improve-
ment, PEFR
30 None se-
vere enough to
warrant with-
drawal
Bronchodila-
tors in last 6 h,
steroids in last
12 h
Neb-
ulised salbuta-
mol, IV hy-
drocortisone,
IV amino-
phylline at
clinicians’ dis-
cretion
ASS: Asthma Severity Score; BP: blood pressure; ED: emergency department; FEV1: Forced expiratory volume in 1 second; h: hour(s)
HR: heart rate; IV: intravenous; MgSO : magnesium sulfate; PEF: Peak Expiratory Flow Rate; SAEs: serious adverse events
Table 3. Summary of Interventions
Study (N) Magnesium sulfate Control
Dose N Co-
interventions
Dose N Co-
interventions
MgSO and SABA and Ipratropium bromide versus SABA and Ipratropium
Ashtekar 2008 2.5 mL
isotonic MgSO
(151 mg /dose)
7 500 mcg Iprat-
ropium bromide
2.5 mg salbuta-
mol or 5 mg
salbutamol (de-
pending on age)
3 times per h
2.5 mL of iso-
tonic saline)
10 Same as for
MgSO group
Drobina 2006 150 mg MgSO
(0.3 mL of 50%
MgSO
heptahydrate)
60 Albuterol sulfate
(0.5%) 5
mg/mL) and 0.5
mg ipratropium
bromide (0.02%
inhalation solu-
tion)
(frequency*)
No placebo so
volume will be
less: i.e. blinding
may be an issue)
50 Same as for
MgSO group
Gallegos-
Solórzano 2010
3 mL (333 mg)
of 10% isotonic
MgSO (1 g/10
mL)
60 (30
withdrawals)
2.5 mg albuterol
and 500
mcg ipratropium
3 doses per hour
3 mL isotonic
saline
52 (22
withdrawals)
Same as for
MgSO group
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Table 3. Summary of Interventions (Continued)
Gaur 2008 3 mL (3.2 g%)
isotonic MgSO
30 Salbu-
tamol and ipra-
tropium (dose*,
frequency*)
Saline 30 Same as for
MgSO group
Goodacre 2013 2 mmol MgSO 339 (7
withdrawal)
7.5 mL
0.9% NaCl neb-
ulised, 3 doses;
100 mL 0.9%
NaCl IV once,
BTS/SIGN stan-
dard treatments
plus others at
clinicians’ discre-
tion
7.5 mL 0.9%
saline nebulised,
3 doses, 100 mL
0.9% NaCl IV
once
364 (7
withdrawal)
BTS/SIGN stan-
dard treatments
plus others at
clinicians’ discre-
tion
Hossein 2016 3
mL (260 mmol/
L) MgSO4
25 2.5 mg salbuta-
mol, 0.5
mg ipratropium
neb-
ulised every 20
to 60 minutes,
50 mg oral pred-
nisolone (once*)
3mL0.9%NaCl 25 Same as for
MgSO group
Powell 2013 2.5
mL 250 mmol/L
MgSO
252 (13 with-
drawals)
3 doses every 20
min. Hospital-
defined conven-
tional treatment
2.5 mL isotonic
saline
256 (10 with-
drawals)
Same as for
MgSO group
MgSO4 and SABA versus SABA
Abreu-Gonzalez
2002
2 mL MgSO
(isotonic)
13 400mcg salbuta-
mol
(once*)
2 mL of a physi-
ological serum of
an inhaled form
11 patients
11 400mcg salbuta-
mol
Aggarwal 2006 1 mL of 500 mg/
mL MgSO
50 1 mL salbutamol
(dose*, 8 mL dis-
tilled water, (295
mOsml/kg) 3
times per h
ultrasonic nebu-
liser
7.5 mL normal
saline
50 1 mL salbutamol
(dose*),
1.5 mL distilled
water
(287mOsml/kg)
3 times per h
Ahmed 2013 MgSO (dose*
frequency*)
60 Not recorded Nor-
mal saline (dose*
frequency*)
60 Not recorded
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Table 3. Summary of Interventions (Continued)
Alansari 2015 800 mg (15 mL)
MgSO
208 (17 with-
drawals)
5 mg albuterol,
divided
into 3 doses over
1 h.Methylpred-
nisolone 1 mg/
kg IV every 12
h. 3 doses neb-
ulized 1 mL al-
buterol (5 mg/
mL)
, 250 mcg ipra-
tropium, 2 mL
normal saline be-
fore trial doses
started
15 mL 0.9%
NaCl
192 (18 with-
drawals)
Same as for
MgSO group
Badawy 2014 500 mg (1mL)
MgSO
30 1 mL salbutamol
solution (dose*),
8 mL
0.9% NaCl, max
3 doses with 20
mins apart. 100
mg hydrocorti-
sone IV, 500 mg
aminophylline
IV (once*)
1mL0.9%NaCl 30 Same as for
MgSO group
Bessmertny
2002
MgSO
(384 mg)
37 (3
withdrawals)
Followed by ( i.
e. not mixed) al-
buterol 2.5 mg/
mL 3 times per h
Normal saline
(no volume doc-
umented)
37 (3
withdrawals)
Same as for
MgSO group
Dadhich 2005 MgSO 26 No doses in
any group or co-
interventions de-
scribed
Not stated 24 No doses in
any group or co-
interventions de-
scribed
Hughes 2003 2.5 mL isotonic
MgSO
(250 mmol/L
151 mg)
28 patients
28 2.5 mg salbuta-
mol 3 times per
30 minutes
2.5 mL normal
saline
24 Same as for
MgSO group
Khashabi 2008 Isotonic MgSO
(dose*,
frequency*)
* Salbutamol
(dose*)
2.5 mL normal
saline
(frequency*)
* Same as for
MgSO group
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Table 3. Summary of Interventions (Continued)
Kokturk 2005 Isotonic MgSO
(2.5 mL)
14 Salbutamol
(dose*) 3
times per h then
1 per h for 3 h
2.5 mL normal
saline
12 Same as for
MgSO group
Mo-
hammedzadeh
2014
3
mL 7.5%MgSO
40 0.15 mg/
kg salbutamol 3
doses, every 20
min
3 mL normal
saline
40 Same as for
MgSO group
Mahajan 2004 2.5 mL Isotonic
(6.3%) MgSO
solution
31 Albuterol 2.5mg
1 dose
2.5 mL normal
saline
31 Same as for
MgSO group
Nannini 2000 3 mL isotonic
MgSO
(286 mOsml, 7.
5%, 225 mg)
19 0.5 mL 2.5 mg
salbutamol
1 dose*
3 mL normal
saline
16 Same as for
MgSO group
Sarhan 2016 2.5 mL MgSO4
(100 mg), 0.5
mL salbutamol
(2.5 mg)
10 4 doses
at 20 min inter-
vals. If needed:
additional nebu-
lised salbutamol,
IV hy-
drocortisone, IV
aminophylline
2.5 mL isotonic
saline
10 Same as for
MgSO4 group
Turker 2017 1
mL magnesium
sulfate (15%) +
1.5 mL isotonic
saline
50 3 doses at 20min
intervals. Also
nebulised salbu-
tamol (0.15 mg/
kg), methylpred-
nisolone 1 mg/
kg IV; Oxygen
was given to pa-
tients with SaO2
≤ 95%
1.5 mL isotonic
saline
50 Same as for
MgSO group
MgSO versus SABA
Dadhich 2005 MgSO 21 No doses in
any group or co-
interventions de-
scribed
Not stated 24 No doses in
any group or co-
interventions de-
scribed
Mangat 1998 3.2% so-
lution MgSO =
95 mg)
16 4 doses every 20
minutes
3 mL (2.5 mg)
salbutamol
17 Four doses every
20 minutes
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Table 3. Summary of Interventions (Continued)
Meral 1996 2 mL MgSO
(280 mmol/L)
20 1* dose given
over 10 to 15
minutes
Salbutamol 2.5
mg in 2.5 mL
20 1 dose* given
over 10 to 15
minutes
Neki 2006 20 patients
3.2 G % MgSO
20 4 doses every 20
min
3 mL of 25 mg*
salbuta-
mol (likely dec-
imal point miss-
ing)
20 Same as for
MgSO4 group
Sarhan 2016 3 mL (100 mg)
MgSO4
10 4 doses
at 20 min inter-
vals. If needed:
additional nebu-
lised salbutamol,
IV hy-
drocortisone, IV
aminophylline
0.5 mL salbuta-
mol (2.5 mg)
10 Same as for
MgSO group
TOTAL: 2907
randomised to
comparisons of
interest.
130 withdrawn,
2777
completed
TOTAL: 1476
randomised, 70
withdrawn
= 1406 com-
pleted interven-
tion
TOTAL: 1431
randomised, 60
with-
drawn = 1371
completed con-
trol
* denotes uncertainty
Table 4. Outcomes
Study ID (au-
thor, date of
publication)
Review primary out-
comes
Review secondary outcomes
FEV1 PEF Clinical sever-
ity scores
Hospital
admissions
Duration of
symptoms
Vital signs Adverse effects
MgSO and SABA and Ipratropium bromide versus SABA and Ipratropium
Ashtekar 2008 N N Y N N N Y
Drobina 2006 N P N N N N P
Gallegos-
Solórzano
2010
Y N N N N N Y
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Table 4. Outcomes (Continued)
Gaur 2008 Y N N N N N N
Goodacre
2013
N Y N Y N Y Y
Hossein 2016 N Y Y Y N Y N
Powell 2013 N N Y P N N Y
MgSO4 and SABA versus SABA
Abreu-
Gonzalez
2002
Y Y N N N N N
Aggarwal
2006
N Y N Y N Y Y
Ahmed 2013 N P N N N N N
Alansari 2015 N N Y P N N Y
Badawy 2014 Y Y N N N Y N
Bessmertny
2002
P N N N N N Y
Dadhich 2005 P P N N N N Y
Hughes 2003 Y N N Y N N Y
Khashabi
2008
N N N N N N N
Kokturk 2005 N Y P Y N N Y
Mahajan 2004 Y N N Y N N Y
Mo-
hammedzadeh
2014
N Y Y N N N N
Nannini 2000 N Y N Y N N Y
Sarhan 2016 N Y Y N N Y N
Turker 2017 N N Y Y N N Y
MgSO versus SABA
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Table 4. Outcomes (Continued)
Dadhich 2005 P P N N N N Y
Mangat 1998 N Y N Y N N Y
Meral 1996 N Y N N N N Y
Neki 2006 N Y N N N Y N
Sarhan 2016 N Y Y N N Y N
N the study did not report the outcome but it is not clear whether the outcome was measured or not
Y full reporting
P partial reporting
WH A T ’ S N E W
Last assessed as up-to-date: 6 September 2017.
Date Event Description
6 September 2017 New citation required and conclusions have changed Nine new trials with 2051 participants were added to
the 896 (16 trials) in the previous version of the review.
We re-ordered the comparisons to reflect current asthma
management
The evidence has been strengthened by the addition of
several large well-conducted trials. We are more con-
fident that the treatment is likely to be well tolerated;
however, there remains uncertainty about modest ben-
efits for lung function and hospital admission when
added to standard therapies
6 September 2017 New search has been performed New literature search run and incorporated.
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H I S T O R Y
Protocol first published: Issue 1, 2004
Review first published: Issue 2, 2005
Date Event Description
28 September 2012 New citation required and conclusions have changed Ten new trials with 600 participants added to the 296
in the previous version of the review. We added a new
comparison of inhaled magnesium sulfate in addition
to inhaled β2 -agonist and ipratropium bromide.
The evidence remains inconclusive, but whilst there is
no good evidence that inhaled magnesium sulfate can
be used as a substitute for inhaled beta2-agonists, there
is a suggestion of benefit in pulmonary function when
used in addition to inhaled beta2-agonists (with or
without ipratropium) in severe asthma exacerbations
28 September 2012 New search has been performed New literature search run.
28 July 2008 Amended Converted to new review format.
22 August 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
For the 2017 update, RK and RN identified the included studies, extracted data, assessed risk of bias and analysed the data. RN and
SM performed the GRADE assessments. RK and RN drafted the manuscript CP provided advice. All authors read and approved the
final version for publication.
D E C L A R A T I O N S O F I N T E R E S T
Drs. Hughes and Beasley were involved as Primary and Co-investigator on one of the trials included in this review (Hughes 2003).
Dr Powell was a co-author of the pilot work completed in Ashtekar 2008 and was the chief investigator of the MAGNETIC study in
children (Powell 2013). Dr Powell was not involved in the selection of studies for inclusion, data extraction, risk of bias assessment or
GRADE assessments.
None of the other review authors has any known conflict of interest.
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S O U R C E S O F S U P P O R T
Internal sources
• Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.
• National Institute of Health Research (SJM), UK.
External sources
• Alberta Cancer Board, Canada.
• Canadian Institutes of Health Research (CIHR), Ottawa (BHR), Canada.
• Canadian Institutes of Health Research (CIHR), Ottawa, ON (BH Rowe)„ Canada.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the 2012 update the ’Risk of bias’ tool has been updated to that advised in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). Three new review authors were added and the sensitivity analyses have been amended to
investigating risk of bias rather than methodological quality.
In 2017 the following changes were made.
• Background, Results and Discussion substantially re-drafted.
• Comparisons re-ordered to reflect current clinical practice.
• We chose to present outcomes at, or as close to as possible, 60 minutes from baseline. This time point was decided by consensus.
• We performed a post-hoc sensitivity analysis excluding trials with unusually small standard deviations.
• We chose to exclude one study from the meta-analyses due to concerns about baseline imbalance and the narrow population
recruited (pregnant women only) (Badawy 2014).
• We added a ’Summary of findings’ table.
• Two review authors stepped down (Richard Beasley and Kerry Dwan) and two new authors were added (Rachel Knightly and
Rebecca Normansell).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists [∗administration & dosage]; Anti-Asthmatic Agents
[∗administration & dosage]; Asthma [∗drug therapy]; Bronchodilator Agents [administration & dosage]; Disease Progression; Drug
Therapy, Combination [methods]; Hospitalization; Ipratropium [administration & dosage]; Magnesium Sulfate [∗administration &
dosage]; Randomized Controlled Trials as Topic; Respiratory Function Tests
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MeSH check words
Adult; Child; Humans
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